PMID
Article Title
Citation
Organization
Download
View Data
A metabolically stable tight-binding transition-state inhibitor of glyoxalase-I.
Bioorg Med Chem Lett 16: 6039-42 (2006)
University of Minnesota
5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-epsilon kinase.
Bioorg Med Chem Lett 16: 6236-40 (2006)
Gsk
Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.
Bioorg Med Chem Lett 16: 5943-7 (2006)
University of Bonn
The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Bioorg Med Chem Lett 16: 5973-7 (2006)
Procter and Gamble Pharmaceuticals
Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction.
Bioorg Med Chem Lett 16: 5958-62 (2006)
Abbott Laboratories
Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands.
Bioorg Med Chem Lett 16: 6043-8 (2006)
Johnson & Johnson Pharmaceutical
Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors.
Bioorg Med Chem Lett 16: 5907-12 (2006)
Merck Research Laboratories
Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
Bioorg Med Chem Lett 16: 6001-5 (2006)
Ildong Pharmaceutical
Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.
J Nat Prod 69: 1341-6 (2006)
Leopold-Franzens-Universit£T
Oculatol, oculatolide, and A-nor sterols from the sponge Haliclona oculata.
J Nat Prod 69: 1330-4 (2006)
Peking University
Antidepressant principles of the roots of Polygala tenuifolia.
J Nat Prod 69: 1305-9 (2006)
Medical and Pharmaceutical Industry Technology and Development Center
Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis.
J Nat Prod 69: 1295-9 (2006)
Griffith University
Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides.
Bioorg Med Chem Lett 16: 5968-72 (2006)
Merck And
Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists.
Bioorg Med Chem Lett 16: 6086-90 (2006)
Abbott Laboratories
A series of novel, potent, and selective histone deacetylase inhibitors.
Bioorg Med Chem Lett 16: 5948-52 (2006)
Irbm/Merck Research Laboratories
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
NA
Kirin Brewery, Co., Ltd.
Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
Bioorg Med Chem Lett 16: 5878-82 (2006)
Peking Union Medical College
Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors.
Bioorg Med Chem Lett 16: 5731-5 (2006)
Glaxosmithkline
Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
Bioorg Med Chem Lett 16: 5953-7 (2006)
Glaxosmithkline
Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Bioorg Med Chem Lett 16: 6116-9 (2006)
Pfizer
Enzyme inhibition potency enhancement by active site metal chelating and hydrogen bonding induced conformation-restricted cyclopropanecarbonyl derivatives.
Bioorg Med Chem Lett 16: 6024-7 (2006)
Tunghai University
Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
Bioorg Med Chem Lett 16: 6063-6 (2006)
Johnson & Johnson Pharmaceutical
3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.
Bioorg Med Chem Lett 16: 6049-53 (2006)
Merck Research Laboratories
Structure-activity relationships for a novel series of thiazolyl phenyl ether derivatives exhibiting potent and selective acetyl-CoA carboxylase 2 inhibitory activity.
Bioorg Med Chem Lett 16: 6078-81 (2006)
Abbott Laboratories
Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis.
Bioorg Med Chem Lett 16: 6067-72 (2006)
Wyeth Research
Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Bioorg Med Chem Lett 16: 6120-3 (2006)
Pfizer
Inhibitors of unactivated p38 MAP kinase.
Bioorg Med Chem Lett 16: 6102-6 (2006)
Johnson and Johnson Pharmaceutical Research and Development
Aminopyridine carboxamides as c-Jun N-terminal kinase inhibitors: targeting the gatekeeper residue and beyond.
Bioorg Med Chem Lett 16: 5723-30 (2006)
Abbott Laboratories
Identification and optimisation of 5-amino-7-aryldihydro-1,4-diazepines as 5-HT2A ligands.
Bioorg Med Chem Lett 16: 6058-62 (2006)
Merck Sharp and Dohme Research Laboratories
Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches.
Bioorg Med Chem Lett 16: 5993-7 (2006)
Vernalis (R&D)
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.
J Med Chem 49: 5794-803 (2006)
Purdue University
Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
J Med Chem 49: 5785-93 (2006)
University of Antwerp
HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
J Med Chem 49: 5777-84 (2006)
Academy of Sciences of The Czech Republic
[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines.
J Med Chem 49: 5769-76 (2006)
University of Regensburg
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
J Med Chem 49: 5759-68 (2006)
University of Milano-Bicocca
Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands.
J Med Chem 49: 5750-8 (2006)
Hokkaido University
Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites.
J Med Chem 49: 5710-27 (2006)
Yale University
Iminosugars as potential inhibitors of glycogenolysis: structural insights into the molecular basis of glycogen phosphorylase inhibition.
J Med Chem 49: 5687-701 (2006)
The National Hellenic Research Foundation
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
J Med Chem 49: 5671-86 (2006)
Amgen
Identification of a novel 4-aminomethylpiperidine class of M3 muscarinic receptor antagonists and structural insight into their M3 selectivity.
J Med Chem 49: 5653-63 (2006)
Tsukuba Research Institute
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
J Med Chem 49: 5649-52 (2006)
Eli Lilly
Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
J Med Chem 49: 5645-8 (2006)
The Johns Hopkins University School of Medicine
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.
Bioorg Med Chem Lett 16: 5584-9 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein.
Bioorg Med Chem Lett 16: 5805-8 (2006)
University of Michigan
A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors.
Bioorg Med Chem Lett 16: 5598-601 (2006)
Procter and Gamble Pharmaceuticals
Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
Bioorg Med Chem Lett 16: 5744-7 (2006)
University of Dundee
Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.
Antimicrob Agents Chemother 50: 3631-7 (2006)
National Center For Genetic Engineering and Biotechnology At Thailand
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Cancer Res 66: 8715-21 (2006)
Amgen
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
Bioorg Med Chem Lett 16: 5748-51 (2006)
Merck Sharp & Dohme Research Laboratories
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.
Bioorg Med Chem Lett 16: 5752-6 (2006)
Merck Sharp & Dohme Research Laboratories
Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
J Mol Biol 362: 979-93 (2006)
Osaka University of Pharmaceutical Sciences
Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
Bioorg Med Chem Lett 16: 5897-901 (2006)
Merck Research Laboratories
Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.
Bioorg Med Chem Lett 16: 5773-7 (2006)
University of California
The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Bioorg Med Chem Lett 16: 5778-83 (2006)
Johnson & Johnson Pharmaceutical
Naphtho[2,3-b][1,4]-thiazine-5,10-diones and 3-substituted-1,4-dioxo-1,4-dihydronaphthalen-2-yl-thioalkanoate derivatives: synthesis and biological evaluation as potential antibacterial and antifungal agents.
Bioorg Med Chem Lett 16: 5883-7 (2006)
Lucknow University
Synthesis of 3,6-bis[H-Tyr/H-Dmt-NH(CH2)m,n]-2(1H)pyrazinone derivatives: function of alkyl chain length on opioid activity.
Bioorg Med Chem Lett 16: 5793-6 (2006)
Kobe Gakuin University
p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold.
Bioorg Med Chem Lett 16: 5468-71 (2006)
Merck Research Laboratories
p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
Bioorg Med Chem Lett 16: 5809-13 (2006)
Merck Research Laboratories
Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors.
Bioorg Med Chem Lett 16: 5832-5 (2006)
Virginia Commonwealth University
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Bioorg Med Chem Lett 16: 5840-3 (2006)
Friedrich-Schiller-UniversitäT Jena
Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA.
Bioorg Med Chem Lett 16: 5605-9 (2006)
Saarland University
Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.
Bioorg Med Chem Lett 16: 5567-71 (2006)
Astrazeneca
Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.
Bioorg Med Chem Lett 16: 5498-502 (2006)
Harvard Medical School
Synthesis and structure-activity relationships of 3-phenyl-2-propenamides as inhibitors of glycogen phosphorylase a.
Bioorg Med Chem Lett 16: 5892-6 (2006)
Glaxosmithkline
Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers.
Bioorg Med Chem Lett 16: 5855-8 (2006)
Procter and Gamble Pharmaceuticals
A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands.
Bioorg Med Chem Lett 16: 5646-9 (2006)
Johnson and Johnson Pharmaceutical Research and Development
Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.
Bioorg Med Chem Lett 16: 5859-63 (2006)
Procter & Gamble Pharmaceuticals
Synthesis and alpha4beta2 nicotinic affinity of unichiral 5-(2-pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes.
Bioorg Med Chem Lett 16: 5610-5 (2006)
University of Milan
Potent, selective pyrimidinetrione-based inhibitors of MMP-13.
Bioorg Med Chem Lett 16: 5822-6 (2006)
Pfizer
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
J Med Chem 49: 5640-3 (2006)
Harvard Medical School
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.
J Med Chem 49: 5635-9 (2006)
Rensselaer Polytechnic Institute
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
J Med Chem 49: 5610-7 (2006)
University of Cagliari
Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor.
J Med Chem 49: 5597-609 (2006)
Research Triangle Institute
Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
J Med Chem 49: 5587-96 (2006)
Hokkaido University
3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor.
J Med Chem 49: 5578-86 (2006)
Università
5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase.
J Med Chem 49: 5562-70 (2006)
Instituto De QuíMica MéDica (Csic)
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
J Med Chem 49: 5544-51 (2006)
Istituto Di Biostrutture E Bioimmagini-Cnr
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.
J Med Chem 49: 5532-43 (2006)
National Institute of Diabetes and Digestive and Kidney Diseases
Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge.
J Med Chem 49: 5491-500 (2006)
Institute of Science
Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
J Med Chem 49: 5470-7 (2006)
University of Oxford
Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phenylethanolamine N-methyltransferase.
J Med Chem 49: 5424-33 (2006)
University of Kansas
Uncompetitive antagonism of AMPA receptors: Mechanistic insights from studies of polyamine toxin derivatives.
J Med Chem 49: 5414-23 (2006)
The Danish University of Pharmaceutical Sciences
Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.
J Med Chem 49: 5411-3 (2006)
Friedrich-Schiller-UniversitäT Jena
A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies.
J Med Chem 49: 5404-7 (2006)
Irbm (Merck Research Laboratories Rome)
Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
Nat Chem Biol 2: 543-50 (2006)
University of Illinois
Thermodynamic penalty arising from burial of a ligand polar group within a hydrophobic pocket of a protein receptor.
J Mol Biol 362: 994-1003 (2006)
University of Leeds
Epibatidine isomers and analogues: structure-activity relationships.
Bioorg Med Chem Lett 16: 5493-7 (2006)
University of Leicester
Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.
Bioorg Med Chem Lett 16: 5561-6 (2006)
Valeant Pharmaceuticals Research & Development
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3.
Bioorg Med Chem Lett 16: 5633-8 (2006)
Procter and Gamble Pharmaceuticals
N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
Bioorg Med Chem Lett 16: 5513-6 (2006)
Glaxosmithkline
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
J Nat Prod 69: 1180-7 (2006)
Australian Institute of Marine Science
Chemical probes of UDP-galactopyranose mutase.
Chem Biol 13: 825-37 (2006)
University of Wisconsin-Madison
Comparison between two classes of selective EP(3) antagonists and their biological activities.
Bioorg Med Chem Lett 16: 5639-42 (2006)
Merck Frosst Centre For Therapeutic Research
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.
Bioorg Med Chem Lett 16: 5546-50 (2006)
Targegen
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2.
Bioorg Med Chem Lett 16: 5488-92 (2006)
Gnf
Inhibitory effect of carboxylic acid group on hERG binding.
Bioorg Med Chem Lett 16: 5507-12 (2006)
Portola Pharmaceuticals
Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.
Bioorg Med Chem Lett 16: 5462-7 (2006)
University of Arizona
Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors.
Bioorg Med Chem Lett 16: 5517-22 (2006)
Procter and Gamble Pharmaceuticals
Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.
Bioorg Med Chem Lett 16: 5691-4 (2006)
Eli Lilly
Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
Bioorg Med Chem Lett 16: 5538-41 (2006)
Glaxosmithkline
Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.
Bioorg Med Chem Lett 16: 5555-60 (2006)
Abbott Laboratories
2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.
Bioorg Med Chem Lett 16: 5695-9 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
Nat Chem Biol 2: 551-8 (2006)
The Scripps Research Institute
Design of inhibitors against guanase: synthesis and biochemical evaluation of analogues of azepinomycin.
Bioorg Med Chem Lett 16: 5551-4 (2006)
University of Maryland
Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
Bioorg Med Chem 14: 7736-44 (2006)
Hokuriku University
Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis.
Bioorg Med Chem Lett 16: 5659-63 (2006)
Procter and Gamble Pharmaceuticals
Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata.
Bioorg Med Chem Lett 16: 5580-3 (2006)
National Research Laboratory of Lipid Metabolism and Atherosclerosis
Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime.
Bioorg Med Chem Lett 16: 5576-9 (2006)
National Research Laboratory of Lipid Metabolism and Atherosclerosis
Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists.
Bioorg Med Chem Lett 16: 5294-7 (2006)
A.V. Bogatsky Physico-Chemical Institute of The National Academy of Sciences of Ukraine
Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
Bioorg Med Chem Lett 16: 5373-7 (2006)
Merck Research Laboratories
2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists.
Bioorg Med Chem Lett 16: 5270-4 (2006)
Merck Research Laboratories
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
Bioorg Med Chem Lett 16: 5650-3 (2006)
Chulalongkorn University
4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists.
Bioorg Med Chem Lett 16: 5275-9 (2006)
Merck Research Laboratories
Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics.
J Biol Chem 281: 32784-95 (2006)
Incyte
WAY-100635 is a potent dopamine D4 receptor agonist.
Psychopharmacology (Berl) 188: 244-51 (2006)
Purdue University
Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists.
J Med Chem 49: 5382-5 (2006)
National University of Singapore
Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
J Med Chem 49: 5363-71 (2006)
Università
7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
J Med Chem 49: 5352-62 (2006)
Conforma Therapeutics
Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
J Med Chem 49: 5339-51 (2006)
Instituto De QuíMica MéDica (Csic)
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
J Med Chem 49: 5333-8 (2006)
University of Bristol
Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.
J Med Chem 49: 5316-23 (2006)
Purdue University
Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.
J Med Chem 49: 5309-15 (2006)
The University of Utah
Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides.
J Med Chem 49: 5282-90 (2006)
The University of Tennessee Health Science Center
Synthesis and structure-activity relationships of truncated bisubstrate inhibitors of aminoglycoside 6'-N-acetyltransferases.
J Med Chem 49: 5273-81 (2006)
Mcgill University
Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance.
J Med Chem 49: 5252-61 (2006)
Purdue University
Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening.
J Med Chem 49: 5232-44 (2006)
Montana State University
Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors.
J Med Chem 49: 5217-25 (2006)
Virginia Commonwealth University
Calcium channel antagonists discovered by a multidisciplinary approach.
J Med Chem 49: 5206-16 (2006)
University of Perugia
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
J Med Chem 49: 5154-61 (2006)
National Defense Medical Center
Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations.
J Med Chem 49: 5141-53 (2006)
University of Cambridge
N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity.
J Med Chem 49: 5119-28 (2006)
Cnrs
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
J Med Chem 49: 5093-109 (2006)
Abbott Laboratories
Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
J Med Chem 49: 5051-8 (2006)
Istituto Di Cristallografia
Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.
J Med Chem 49: 5047-50 (2006)
Institut De Recherches Servier
Synthesis and monoamine transporter affinity of 2beta-carbomethoxy-3beta-(4'-p-substituted phenyl)-piperidine analogs of cocaine.
Bioorg Med Chem Lett 16: 5222-5 (2006)
Yale University
Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.
Bioorg Med Chem Lett 16: 5303-8 (2006)
Novo Nordisk
Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors.
Bioorg Med Chem Lett 16: 5616-20 (2006)
Procter and Gamble Pharmaceuticals
Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles.
Bioorg Med Chem Lett 16: 5265-9 (2006)
Nih
Design and synthesis of a series of novel pyrazolopyridines as HIF-1alpha prolyl hydroxylase inhibitors.
Bioorg Med Chem Lett 16: 5687-90 (2006)
Procter and Gamble Pharmaceuticals
Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.
Bioorg Med Chem Lett 16: 4987-93 (2006)
Boehringer Ingelheim Pharmaceuticals
Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
Bioorg Med Chem Lett 16: 5439-44 (2006)
University of California
Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.
Bioorg Med Chem Lett 16: 5398-402 (2006)
Seoul National University
Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters.
Bioorg Med Chem Lett 16: 5018-21 (2006)
University of Kentucky
Novel benzimidazole-based MCH R1 antagonists.
Bioorg Med Chem Lett 16: 4994-5000 (2006)
Glaxosmithkline
New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
Bioorg Med Chem Lett 16: 5226-30 (2006)
Glaxosmithkline
Synthesis of bicyclic molecular scaffolds (BTAa): an investigation towards new selective MMP-12 inhibitors.
Bioorg Med Chem 14: 7392-403 (2006)
University of Florence
Synthesis and biological evaluation of heterocycle containing adamantane 11beta-HSD1 inhibitors.
Bioorg Med Chem Lett 16: 5414-9 (2006)
Abbott Laboratories
Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
Bioorg Med Chem Lett 16: 5127-31 (2006)
Gakushuin University
Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
ChemMedChem 1: 130-9 (2006)
Universit�� Degli Studi Di Parma
Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
ChemMedChem 1: 106-17 (2006)
Philipps-Universität Marburg
Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
ChemMedChem 1: 96-105 (2006)
Bayer Healthcare
Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis.
Bioorg Med Chem Lett 16: 5041-6 (2006)
Washington University
Aza-stilbenes as potent and selective c-RAF inhibitors.
Bioorg Med Chem Lett 16: 5378-83 (2006)
Glaxosmithkline
Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
Bioorg Med Chem Lett 16: 5368-72 (2006)
Cephalon
Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains.
Bioorg Med Chem Lett 16: 5384-8 (2006)
University of Siena
Synthesis of highly substituted dibenzo[b,f]azocines and their evaluation as protein kinase inhibitors.
Bioorg Med Chem Lett 16: 5360-3 (2006)
St. Jude Children'S Research Hospital
Synthesis and structural activity relationship of 11beta-HSD1 inhibitors with novel adamantane replacements.
Bioorg Med Chem Lett 16: 5408-13 (2006)
Abbott Laboratories
The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme.
Bioorg Med Chem Lett 16: 5084-7 (2006)
Mrc Laboratory of Molecular Biology, Hills Road, Cambridge, Cb2 2Qh
Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases.
Bioorg Med Chem Lett 16: 5427-31 (2006)
Schering-Plough Research Institute
1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.
Bioorg Med Chem Lett 16: 5432-5 (2006)
Clemson University
Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.
Bioorg Med Chem Lett 16: 5052-6 (2006)
Merck Research Laboratories
Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists.
Bioorg Med Chem Lett 16: 5066-72 (2006)
Amgen
Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase.
Bioorg Med Chem Lett 16: 5102-6 (2006)
Imclone Systems
Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase.
J Med Chem 49: 5018-22 (2006)
University of Minnesota
NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein.
J Med Chem 49: 5013-7 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis of anthranylaldoxime derivatives as estrogen receptor ligands and computational prediction of binding modes.
J Med Chem 49: 5001-12 (2006)
Università
Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.
J Med Chem 49: 4992-5000 (2006)
University Chemical Laboratory
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
J Med Chem 49: 4981-91 (2006)
Amgen
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
J Med Chem 49: 4971-80 (2006)
Taigen Biotechnology
Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.
J Med Chem 49: 4937-45 (2006)
University of Toronto
Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches.
J Med Chem 49: 4912-25 (2006)
University of Bari Aldo Moro
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.
J Med Chem 49: 4896-911 (2006)
University of Auckland
Brunsvicamides A-C: sponge-related cyanobacterial peptides with Mycobacterium tuberculosis protein tyrosine phosphatase inhibitory activity.
J Med Chem 49: 4871-8 (2006)
University of Bonn
Inhibition of kinesin motor proteins by adociasulfate-2.
J Med Chem 49: 4857-60 (2006)
University of Georgia
Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
J Med Chem 49: 4834-41 (2006)
University of Pittsburgh
Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
J Med Chem 49: 4809-12 (2006)
Nagoya City University
Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring.
J Med Chem 49: 4805-8 (2006)
Astrazeneca R&D Boston
Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.
J Med Chem 49: 4801-4 (2006)
Merck Research Laboratories
Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.
Bioorg Med Chem Lett 16: 5199-202 (2006)
University of Southern California
A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.
Bioorg Med Chem Lett 16: 5057-61 (2006)
Eli Lilly
Identification of potent agonists of photoreceptor-specific nuclear receptor (NR2E3) and preparation of a radioligand.
Bioorg Med Chem Lett 16: 5001-4 (2006)
Merck
Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity.
Bioorg Med Chem Lett 16: 5445-50 (2006)
Procter and Gamble Pharmaceuticals
Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta.
Bioorg Med Chem Lett 16: 5231-7 (2006)
F. Hoffmann-La Roche
Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
Bioorg Med Chem Lett 16: 5022-7 (2006)
Daiichi Asubio Medical Research Laboratories
Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors.
Bioorg Med Chem Lett 16: 5107-11 (2006)
Gnf
Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
Bioorg Med Chem Lett 16: 5244-8 (2006)
Institute of Science and Technology
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
Bioorg Med Chem Lett 16: 5122-6 (2006)
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
Bioorg Med Chem Lett 16: 5112-7 (2006)
Gnf
Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity.
Bioorg Med Chem Lett 16: 5088-92 (2006)
Jerini
Homo-cysteinyl peptide inhibitors of the L1 metallo-beta-lactamase, and SAR as determined by combinatorial library synthesis.
Bioorg Med Chem Lett 16: 5169-75 (2006)
University of Virginia
A general strategy for creating "inactive-conformation" abl inhibitors.
Chem Biol 13: 779-86 (2006)
The Scripps Research Institute
MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.
Chem Biol 13: 711-22 (2006)
Gpc Biotech
A novel class of positive allosteric modulators of AMPA receptors: design, synthesis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, LY2059346.
Bioorg Med Chem Lett 16: 5203-6 (2006)
Eli Lilly
Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells.
J Nat Prod 69: 1095-7 (2006)
Korea Research Institute of Bioscience and Biotechnology
An apigenin-derived xanthine oxidase inhibitor from Palhinhaea cernua.
J Nat Prod 69: 1089-91 (2006)
Nanjing University
Antibiotic bisanthraquinones produced by a streptomycete isolated from a cyanobacterium associated with Ecteinascidia turbinata.
J Nat Prod 69: 1070-3 (2006)
University of Rhode Island
Chemokine receptor CCR-5 inhibitors produced by Chaetomium globosum.
J Nat Prod 69: 1025-8 (2006)
Schering-Plough Research Institute
Biphenyl glycosides from the fruit of Pyracantha fortuneana.
J Nat Prod 69: 1022-4 (2006)
Shenyang Pharmaceutical University
Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
Bioorg Med Chem Lett 16: 4818-21 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease.
Bioorg Med Chem Lett 16: 5183-9 (2006)
Hawaii Biotech
Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
Bioorg Med Chem Lett 16: 4728-32 (2006)
Procter and Gamble Pharmaceuticals
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Bioorg Med Chem Lett 16: 5212-6 (2006)
University of California
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Bioorg Med Chem Lett 16: 4796-9 (2006)
Pharmaceutical Research Institute
Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
Bioorg Med Chem Lett 16: 5176-82 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide.
Bioorg Med Chem Lett 16: 4748-51 (2006)
The University of Tokyo
The discovery and optimization of pyrimidinone-containing MCH R1 antagonists.
Bioorg Med Chem Lett 16: 4723-7 (2006)
Glaxosmithkline
4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.
Bioorg Med Chem Lett 16: 4715-22 (2006)
Merck Research Laboratories
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Bioorg Med Chem Lett 16: 4752-6 (2006)
Kingston University
Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents.
Bioorg Med Chem Lett 16: 5207-11 (2006)
Procter and Gamble Pharmaceuticals
From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist.
Bioorg Med Chem Lett 16: 5217-21 (2006)
Neurogen
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.
Bioorg Med Chem Lett 16: 4738-42 (2006)
Korea Research Institute of Bioscience and Biotechnology
The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
J Am Chem Soc 128: 9699-704 (2006)
The Scripps Research Institute
Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
J Med Chem 49: 4785-9 (2006)
Wyeth Research
Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
J Med Chem 49: 4781-4 (2006)
Korea Research Institute of Chemical Technology
Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.
J Med Chem 49: 4777-80 (2006)
University of Bologna
Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
J Med Chem 49: 4767-76 (2006)
National Center For Scientific Research Demokritos
Potent inhibitors of the Qi site of the mitochondrial respiration complex III.
J Med Chem 49: 4762-6 (2006)
Fmc Stine Research Center
Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic approach.
J Med Chem 49: 4745-61 (2006)
Procter & Gamble Pharmaceuticals
Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109.
J Med Chem 49: 4721-36 (2006)
Central Pharmaceutical Research Institute
Probing the role of the covalent linkage of ferrocene into a chloroquine template.
J Med Chem 49: 4707-14 (2006)
Unit£
Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
J Med Chem 49: 4657-64 (2006)
Paris-Sud University
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
J Med Chem 49: 4650-6 (2006)
University of Kuopio
3'-Substituted 7-halogenoindirubins, a new class of cell death inducing agents.
J Med Chem 49: 4638-49 (2006)
Cnrs
Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
J Med Chem 49: 4623-37 (2006)
Wyeth Research
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin.
J Med Chem 49: 4616-22 (2006)
University of Pennsylvania
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
J Med Chem 49: 4606-15 (2006)
Infinity Pharmaceuticals
Synthesis and monoamine transporter binding properties of 2,3-cyclo analogues of 3beta-(4'-aminophenyl)-2beta-tropanemethanol.
J Med Chem 49: 4589-94 (2006)
Research Triangle Institute
Structure-based design and synthesis of macroheterocyclic peptidomimetic inhibitors of the aspartic protease beta-site amyloid precursor protein cleaving enzyme (BACE).
J Med Chem 49: 4544-67 (2006)
Universite De Montreal At Succursale Centre-Ville
Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.
J Med Chem 49: 4526-34 (2006)
University of Southern California
Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.
J Med Chem 49: 4512-6 (2006)
Vrije Universiteit Amsterdam
Simplified cyclic analogues of bastadin-5. Structure-activity relationships for modulation of the RyR1/FKBP12 Ca2+ channel complex.
J Med Chem 49: 4497-511 (2006)
University of California
Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.
J Med Chem 49: 4487-96 (2006)
Salk Institute
Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.
J Med Chem 49: 4477-86 (2006)
Graduate School of The Chinese Academy of Sciences
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.
J Med Chem 49: 4459-69 (2006)
Abbott Laboratories
Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.
J Med Chem 49: 4455-8 (2006)
Abbott Laboratories
Complexation of adamantyl compounds by beta-cyclodextrin and monoaminoderivatives.
J Phys Chem B 109: 9719-26 (2005)
Universidade De Santiago De Compostela
Synthesis and structure activity relationships of novel non-peptidic metallo-aminopeptidase inhibitors.
Bioorg Med Chem 14: 7241-57 (2006)
Enscmu
New spiro-piperidines as 5-HT2B receptor antagonists.
Bioorg Med Chem Lett 16: 4830-3 (2006)
Hopital Saint-Louis
Binding mode of new (thio)hydantoin inhibitors of fatty acid amide hydrolase: comparison with two original compounds, OL-92 and JP104.
Bioorg Med Chem Lett 16: 4772-6 (2006)
Fundp
Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines.
Bioorg Med Chem Lett 16: 4777-9 (2006)
Laboratory of Medicinal Chemistry University of Antwerp
Identification of novel pyrazole acid antagonists for the EP1 receptor.
Bioorg Med Chem Lett 16: 4767-71 (2006)
Glaxosmithkline
A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5).
Bioorg Med Chem Lett 16: 4792-5 (2006)
Astrazeneca R & D M£Lndal
Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849.
Bioorg Med Chem Lett 16: 4872-8 (2006)
Glaxosmithkline
SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): discovery of antagonist SB-568849.
Bioorg Med Chem Lett 16: 4865-71 (2006)
Glaxosmithkline
Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6.
Bioorg Med Chem Lett 16: 4861-4 (2006)
Fujisawa Pharmaceutical
Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGluR5).
Bioorg Med Chem Lett 16: 4788-91 (2006)
Astrazeneca R&D MöLndal
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.
Bioorg Med Chem Lett 16: 4504-11 (2006)
Merck Research Laboratories
Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.
Nat Chem Biol 2: 434-41 (2006)
The Scripps Research Institute
Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer.
Bioorg Med Chem 14: 6525-38 (2006)
University of Tennessee Health Science Center
Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity.
Bioorg Med Chem Lett 16: 4946-50 (2006)
University of Arizona
Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): identification of a new group III metabotropic glutamate receptor selective agonist.
Bioorg Med Chem Lett 16: 4856-60 (2006)
Faust Pharmaceuticals
Synthesis of tetramic and tetronic acids as beta-secretase inhibitors.
J Comb Chem 8: 480-90 (2006)
Darmstadt Technical University
Himbacine derived thrombin receptor (PAR-1) antagonists: structure-activity relationship of the lactone ring.
Bioorg Med Chem Lett 16: 4969-72 (2006)
Schering-Plough Research Institute
Pharmacophore-based virtual screening: the discovery of novel methionyl-tRNA synthetase inhibitors.
Bioorg Med Chem Lett 16: 4898-907 (2006)
Seoul National University
Propionylpiperazines as human melanocortin-4 receptor ligands.
Bioorg Med Chem Lett 16: 4800-3 (2006)
Neurocrine Biosciences
Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors.
Bioorg Med Chem Lett 16: 4834-8 (2006)
Pfizer
Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2.
Bioorg Med Chem Lett 16: 4922-30 (2006)
Neurocrine Biosciences
Tetrahydroisoquinolines as MCH-R1 antagonists.
Bioorg Med Chem Lett 16: 4917-21 (2006)
Schering-Plough Research Institute
Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
Bioorg Med Chem Lett 16: 4497-503 (2006)
Merck Research Laboratories
Imidazole-dioxolane compounds as isozyme-selective heme oxygenase inhibitors.
J Med Chem 49: 4437-41 (2006)
Queen'S University
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
J Med Chem 49: 4425-36 (2006)
Pfizer
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.
J Med Chem 49: 4409-24 (2006)
Pfizer
A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists.
J Med Chem 49: 4384-91 (2006)
University of Bonn
(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
J Med Chem 49: 4374-83 (2006)
Mitsubishi Pharma
Design and synthesis of novel 2-amino-5-hydroxyindole derivatives that inhibit human 5-lipoxygenase.
J Med Chem 49: 4327-32 (2006)
Friedrich Alexander University Erlangen
Structural requirements for the substrates of the H+/peptide cotransporter PEPT2 determined by three-dimensional quantitative structure-activity relationship analysis.
J Med Chem 49: 4286-96 (2006)
Martin-Luther-University Halle-Wittenberg
Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays.
J Med Chem 49: 4275-85 (2006)
Universite De La Mediterranee
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.
J Med Chem 49: 4269-74 (2006)
Purdue University
Docking and three-dimensional quantitative structure-activity relationship (3D QSAR) analyses of nonsteroidal progesterone receptor ligands.
J Med Chem 49: 4261-8 (2006)
Scientific Computing
From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes.
J Med Chem 49: 4248-60 (2006)
Università
Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and no
J Med Chem 49: 4239-47 (2006)
Wayne State University
Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.
J Med Chem 49: 4216-31 (2006)
Glaxosmithkline
Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
J Med Chem 49: 4208-15 (2006)
University of Perugia
Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase.
J Med Chem 49: 4183-95 (2006)
Cardiff University
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
J Med Chem 49: 4159-70 (2006)
Cardiovascular and Urogenital Centre of Excellence For Drug Discovery
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
J Med Chem 49: 4140-52 (2006)
Ono Pharmaceutical
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
J Med Chem 49: 4127-39 (2006)
Novo Nordisk Research and Development
Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
J Med Chem 49: 4116-26 (2006)
Curacyte Chemistry
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.
J Med Chem 49: 4098-115 (2006)
Parion Sciences
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.
J Med Chem 49: 4085-97 (2006)
Università
Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists.
J Med Chem 49: 4072-84 (2006)
University of Mississippi
Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents.
J Med Chem 49: 4055-8 (2006)
Chugai Pharma Usa
Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction.
J Med Chem 49: 4048-51 (2006)
Chinese Academy of Sciences
Discovery of novel triazole-based opioid receptor antagonists.
J Med Chem 49: 4044-7 (2006)
University of Medicine and Dentistry of New Jersey and Umdnj Informatics Institute
Tetrahydrofluorenones with conformationally restricted side chains as selective estrogen receptor beta ligands.
Bioorg Med Chem Lett 16: 4462-6 (2006)
Merck Research Laboratories
Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.
Bioorg Med Chem Lett 16: 4440-3 (2006)
National Research Institute of Chinese Medicine
Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Bioorg Med Chem Lett 16: 4839-41 (2006)
Tohoku Pharmaceutical University
Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1.
Bioorg Med Chem Lett 16: 4450-7 (2006)
Neurocrine Biosciences
Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus subtilis.
Bioorg Med Chem Lett 16: 4889-92 (2006)
Korea Research Institute of Bioscience and Biotechnology
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
Bioorg Med Chem Lett 16: 4846-51 (2006)
Medical University of Gdansk
Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.
Bioorg Med Chem Lett 16: 4936-40 (2006)
Abbott Laboratories
Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists.
Bioorg Med Chem Lett 16: 4543-7 (2006)
Schering-Plough Research Institute
Inhibition of the enzymatic activity of heme oxygenases by azole-based antifungal drugs.
J Pharmacol Exp Ther 319: 277-84 (2006)
Queen'S University
Modification of the clozapine structure by parallel synthesis.
Bioorg Med Chem Lett 16: 4548-53 (2006)
Schering-Plough Research Institute
Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.
Bioorg Med Chem Lett 16: 4941-5 (2006)
Wyeth Research
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
Bioorg Med Chem Lett 16: 4965-8 (2006)
Bayer Research Center
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Bioorg Med Chem Lett 16: 4908-12 (2006)
Astrazeneca
Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Bioorg Med Chem Lett 16: 4483-7 (2006)
Tehran University of Medical Sciences
N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.
Bioorg Med Chem Lett 16: 4533-6 (2006)
Glaxosmithkline
Synthesis of a red-shifted fluorescence polarization probe for Hsp90.
Bioorg Med Chem Lett 16: 4515-8 (2006)
Memorial Sloan-Kettering Cancer Center
Synthesis of gallic acid based naphthophenone fatty acid amides as cathepsin D inhibitors.
Bioorg Med Chem Lett 16: 4603-8 (2006)
Institute of Medicinal and Aromatic Plants
Studies towards the conception of new selective PPARbeta/delta ligands.
Bioorg Med Chem Lett 16: 4528-32 (2006)
Université
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Bioorg Med Chem Lett 16: 4519-22 (2006)
Kingston University
Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Bioorg Med Chem Lett 16: 4629-32 (2006)
Procter & Gamble Pharmaceuticals
Potent 4-amino-5-azaindole factor VIIa inhibitors.
Bioorg Med Chem Lett 16: 4567-70 (2006)
Celera Genomics
Biotransformation of (-)-ambrox by cell suspension cultures of Actinidia deliciosa.
J Nat Prod 69: 957-9 (2006)
University of Karachi
Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and computational study.
J Nat Prod 69: 945-9 (2006)
Sapienza University of Rome
Synthesis of salvinorin A analogues as opioid receptor probes.
J Nat Prod 69: 914-8 (2006)
The University of Iowa
Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2.
J Nat Prod 69: 887-90 (2006)
Centro De Investigaciones QuíMicas De La Universidad AutóNoma Del Estado De Morelos
New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
J Med Chem 49: 3990-3 (2006)
Vrije Universiteit Brussels
S-alkylated homocysteine derivatives: new inhibitors of human betaine-homocysteine S-methyltransferase.
J Med Chem 49: 3982-9 (2006)
Academy of Sciences of The Czech Republic
Structural studies on bioactive compounds. 40.(1) Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles.
J Med Chem 49: 3973-81 (2006)
University of Nottingham
Activation of murine RNase L by isopolar 2'-phosphonate analogues of 2',5' oligoadenylates.
J Med Chem 49: 3955-62 (2006)
Academy of Sciences of The Czech Republic
2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist.
J Med Chem 49: 3938-47 (2006)
University of Tours
Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
J Med Chem 49: 3926-32 (2006)
Senju Pharmaceutical
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
J Med Chem 49: 3916-25 (2006)
Università
Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents.
J Med Chem 49: 3906-15 (2006)
University of Ferrara
Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns.
J Med Chem 49: 3888-96 (2006)
National Institute of Diabetes and Digestive and Kidney Diseases
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
J Med Chem 49: 3857-71 (2006)
Serono Pharmaceutical Research Institute
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.
J Med Chem 49: 3832-49 (2006)
Abbott Laboratories
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
J Med Chem 49: 3809-25 (2006)
Takeda Pharmaceutical
Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells.
J Med Chem 49: 3800-8 (2006)
University of Pune
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
J Med Chem 49: 3774-89 (2006)
Incyte
Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors.
J Med Chem 49: 3770-3 (2006)
Abbott Laboratories
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
J Med Chem 49: 3766-9 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
J Med Chem 49: 3759-62 (2006)
University of Michigan
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
J Med Chem 49: 3757-8 (2006)
Lundbeck Research Usa
A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties.
J Med Chem 49: 3753-6 (2006)
Neurocrine Biosciences
Synthesis and monoamine transporter affinity of front bridged tricyclic 3beta-(4'-halo or 4'-methyl)phenyltropanes bearing methylene or carbomethoxymethylene on the bridge to the 2beta-position.
Bioorg Med Chem Lett 16: 4661-3 (2006)
Emory University
High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots.
Bioorg Med Chem Lett 16: 4664-7 (2006)
Vanderbilt University
Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors.
Bioorg Med Chem Lett 16: 4612-5 (2006)
University of Cape Town
3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors.
Bioorg Med Chem Lett 16: 4620-3 (2006)
Merck Research Laboratories
Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
Bioorg Med Chem Lett 16: 4616-9 (2006)
University of Cape Town
Rational design of inhibitors that bind to inactive kinase conformations.
Nat Chem Biol 2: 358-64 (2006)
Novartis Research Foundation
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
Bioorg Med Chem Lett 16: 4633-7 (2006)
Pfizer
Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.
Bioorg Med Chem Lett 16: 4638-40 (2006)
Gedeon Richter
Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.
Bioorg Med Chem Lett 16: 4233-6 (2006)
Procter & Gamble Pharmaceuticals
Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease.
Bioorg Med Chem Lett 16: 4405-9 (2006)
Baylor University
Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners.
Bioorg Med Chem Lett 16: 4291-5 (2006)
University of Kentucky
Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase.
Bioorg Med Chem Lett 16: 4420-3 (2006)
Purdue University
Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor.
Bioorg Med Chem Lett 16: 4674-8 (2006)
Neurocrine Biosciences
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).
Bioorg Med Chem Lett 16: 4679-85 (2006)
Mclean Hospital
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
Bioorg Med Chem Lett 16: 4686-91 (2006)
Glaxosmithkline
Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists.
Bioorg Med Chem Lett 16: 4652-6 (2006)
Merck Research Laboratories
Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
Biochemistry 45: 7474-82 (2006)
Abbott Laboratories
Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.
Nat Chem Biol 2: 381-9 (2006)
University of California
Small molecule-based reversible reprogramming of cellular lifespan.
Nat Chem Biol 2: 369-74 (2006)
Korea Advanced Institute of Science and Technology
Synthesis of biotinylated photoaffinity probes based on arylsulfonamide gamma-secretase inhibitors.
Bioorg Med Chem Lett 16: 4184-9 (2006)
University of Tokyo
Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists.
Bioorg Med Chem Lett 16: 4668-73 (2006)
Procter & Gamble Pharmaceuticals
Discovery of protein-protein binding disruptors using multi-component condensations small molecules.
Bioorg Med Chem Lett 16: 3998-4001 (2006)
Pierre Fabre Urologie
Aryloxyethylamines: binding at alpha7 nicotinic acetylcholine receptors.
Bioorg Med Chem Lett 16: 4283-6 (2006)
Virginia Commonwealth University
Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
Bioorg Med Chem Lett 16: 4163-8 (2006)
Chiron
4-Substituted-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with superior pharmacological and pharmacokinetic parameters.
Bioorg Med Chem Lett 16: 4321-5 (2006)
F. Hoffmann-La Roche
Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists.
Bioorg Med Chem Lett 16: 4237-42 (2006)
Neurocrine Biosciences
Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: achieving selectivity against the mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors.
Bioorg Med Chem Lett 16: 4305-10 (2006)
F. Hoffmann-La Roche
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.
Bioorg Med Chem Lett 16: 4339-44 (2006)
Pfizer
Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of N,N'-bis[2-oxo-2H-benzopyran]-3-carboxamides.
Bioorg Med Chem Lett 16: 4135-40 (2006)
Sapienza University of Rome
Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.
Bioorg Med Chem Lett 16: 4252-6 (2006)
Procter & Gamble Pharmaceuticals
N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors.
Bioorg Med Chem Lett 16: 4316-20 (2006)
Università
1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
Bioorg Med Chem Lett 16: 4266-71 (2006)
Abbott Laboratories
Synthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core.
J Med Chem 49: 3743-7 (2006)
FacultéS Universitaires N.D. De La Paix
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
J Med Chem 49: 3719-42 (2006)
Amgen
Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor.
J Med Chem 49: 3701-9 (2006)
University of LièGe
Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.
J Med Chem 49: 3682-92 (2006)
Cv Therapeutics
Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.
J Med Chem 49: 3659-66 (2006)
Abbott Laboratories
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.
J Med Chem 49: 3653-8 (2006)
Universidad De Santiago De Compostela
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
J Med Chem 49: 3636-44 (2006)
Pharmaceutical Research Institute
Fancy bioisosteres: novel paracyclophane derivatives as super-affinity dopamine D3 receptor antagonists.
J Med Chem 49: 3628-35 (2006)
Friedrich-Alexander University
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
J Med Chem 49: 3614-27 (2006)
Merck Research Laboratories
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
J Med Chem 49: 3581-94 (2006)
Pfizer
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
J Med Chem 49: 3563-80 (2006)
Abbott Laboratories
The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
J Med Chem 49: 3544-52 (2006)
Mcgill University Health Center/Royal Victoria Hospital
Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
J Med Chem 49: 3536-43 (2006)
Salk Institute
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
J Med Chem 49: 3520-35 (2006)
Abbott Laboratories
Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
J Med Chem 49: 3509-19 (2006)
University of Athens
Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements.
J Med Chem 49: 3496-500 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
J Med Chem 49: 3485-95 (2006)
National Tsing Hua University
Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.
J Med Chem 49: 3467-77 (2006)
University of Melbourne
The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
J Med Chem 49: 3454-66 (2006)
University of Innsbruck
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.
J Med Chem 49: 3440-3 (2006)
Peking University
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
J Med Chem 49: 3432-5 (2006)
University of Michigan
Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability.
Bioorg Med Chem Lett 16: 4311-5 (2006)
F. Hoffmann-La Roche
The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
Bioorg Med Chem Lett 16: 4257-61 (2006)
Procter and Gamble Pharmaceuticals
beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells.
Bioorg Med Chem Lett 16: 4354-9 (2006)
Kyoto Pharmaceutical University
Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: impacting hERG liability via aryl modifications.
Bioorg Med Chem Lett 16: 4262-5 (2006)
Schering-Plough Research Institute
Discovery of potent CRTh2 (DP2) receptor antagonists.
Bioorg Med Chem Lett 16: 4287-90 (2006)
Astrazeneca R&D Charnwood
Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.
Bioorg Med Chem Lett 16: 4296-9 (2006)
Celera Genomics
p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.
Bioorg Med Chem Lett 16: 4400-4 (2006)
Merck Research Laboratories
Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.
Bioorg Med Chem Lett 16: 4371-5 (2006)
Abbott Laboratories
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.
Bioorg Med Chem Lett 16: 4376-80 (2006)
The Genomics Institute of The Novartis Research Foundation
The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.
Bioorg Med Chem Lett 16: 4360-5 (2006)
Procter and Gamble Pharmaceuticals
Identification of potent and highly selective chiral tri-amine and tetra-amine mu opioid receptors ligands: an example of lead optimization using mixture-based libraries.
Bioorg Med Chem Lett 16: 4331-8 (2006)
Institute For Molecular Studies
The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.
Bioorg Med Chem Lett 16: 4130-4 (2006)
Athersys
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
Bioorg Med Chem Lett 16: 4349-53 (2006)
Pfizer
Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Bioorg Med Chem Lett 16: 4011-5 (2006)
Kingston University
Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivative.
Bioorg Med Chem Lett 16: 4366-70 (2006)
Dartmouth College
CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.
Bioorg Med Chem Lett 16: 4272-8 (2006)
De Montfort University
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
Bioorg Med Chem Lett 16: 4345-8 (2006)
Pfizer
Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
Bioorg Med Chem Lett 16: 4016-20 (2006)
F. Hoffmann-La Roche
Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
J Biol Chem 281: 21469-79 (2006)
University of North Carolina at Chapel Hill
Synthesis and efficacy of 1-[bis(4-fluorophenyl)-methyl]piperazine derivatives for acetylcholinesterase inhibition, as a stimulant of central cholinergic neurotransmission in Alzheimer's disease.
Bioorg Med Chem Lett 16: 3932-6 (2006)
University of Mysore
Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Bioorg Med Chem Lett 16: 4326-30 (2006)
Abbott Laboratories
7-(aryl/heteroaryl-2-ylethynyl)-4-phenylamino-3-quinolinecarbonitriles as new Src kinase inhibitors: addition of water solubilizing groups.
Bioorg Med Chem Lett 16: 3993-7 (2006)
Wyeth Research
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Mol Cancer Ther 5: 1309-17 (2006)
Celera Genomics
Estrogen receptor beta-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere.
Bioorg Med Chem Lett 16: 3896-901 (2006)
Merck Research Laboratories
P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.
Bioorg Med Chem Lett 16: 3960-5 (2006)
Schering-Plough Research Institute
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Bioorg Med Chem Lett 16: 4141-7 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.
Bioorg Med Chem Lett 16: 3906-12 (2006)
Glaxosmithkline
Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.
Bioorg Med Chem Lett 16: 3950-4 (2006)
Lundbeck Research Usa
Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors.
Bioorg Med Chem Lett 16: 3937-42 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and pharmacological characterization of novel fluorescent histamine H2-receptor ligands derived from aminopotentidine.
Bioorg Med Chem Lett 16: 3886-90 (2006)
The University of Kansas
The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors.
Bioorg Med Chem Lett 16: 3981-4 (2006)
H. Lundbeck
Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors.
Bioorg Med Chem Lett 16: 3975-80 (2006)
Valeant Pharmaceutical Research and Development
Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.
Bioorg Med Chem Lett 16: 4085-9 (2006)
Celera Genomics
Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.
Bioorg Med Chem Lett 16: 3927-31 (2006)
Wyeth Research
Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
Bioorg Med Chem Lett 16: 4068-70 (2006)
Korea Research Institute of Bioscience and Biotechnology
Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring.
Bioorg Med Chem Lett 16: 3985-8 (2006)
Gilead Sciences
Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors.
Bioorg Med Chem Lett 16: 3989-92 (2006)
Gilead Sciences
Design and synthesis of selective alpha1B adrenoceptor antagonists.
Bioorg Med Chem Lett 16: 4045-7 (2006)
Toray Industries
Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites.
J Med Chem 49: 3421-5 (2006)
Universita Di Siena
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.
J Med Chem 49: 3416-20 (2006)
University of Naples Federico Ii
Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
J Med Chem 49: 3402-11 (2006)
Johnson & Johnson Pharmaceutical
Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibitors.
J Med Chem 49: 3395-401 (2006)
University of Rhode Island
Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
J Med Chem 49: 3362-7 (2006)
Pfizer
Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.
J Med Chem 49: 3354-61 (2006)
Leiden University
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
J Med Chem 49: 3345-53 (2006)
University of Zurich
Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes.
J Med Chem 49: 3332-44 (2006)
Vanderbilt University School of Medicine
A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors.
J Med Chem 49: 3278-86 (2006)
Università
Synthesis and pharmacological characterization of nicotinic acetylcholine receptor properties of (+)- and (-)-pyrido-[3,4-b]homotropanes.
J Med Chem 49: 3244-50 (2006)
Research Triangle Institute
Conformationally constrained analogues of diacylglycerol. 26. Exploring the chemical space surrounding the C1 domain of protein kinase C with DAG-lactones containing aryl groups at the sn-1 and sn-2 positions.
J Med Chem 49: 3185-203 (2006)
National Cancer Institute-Frederick
New ligands with affinity for the alpha4beta2 subtype of nicotinic acetylcholine receptors. Synthesis, receptor binding, and 3D-QSAR modeling.
J Med Chem 49: 3159-71 (2006)
Neurosearch
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
J Med Chem 49: 3116-35 (2006)
Predix Pharmaceuticals
Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
J Med Chem 49: 3101-15 (2006)
University of Regensburg
Construction of human ghrelin receptor (hGHS-R1a) model using a fragmental prediction approach and validation through docking analysis.
J Med Chem 49: 3077-85 (2006)
University of Milan
cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
J Med Chem 49: 3068-76 (2006)
Pfizer
Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents.
J Med Chem 49: 3064-7 (2006)
University of Messina
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
J Med Chem 49: 3056-9 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.
J Med Chem 49: 3052-5 (2006)
Wyeth Research
New potent P-glycoprotein inhibitors carrying a polycyclic scaffold.
J Med Chem 49: 3049-51 (2006)
University of Bologna
Effect of substitution on novel tricyclic HIV-1 integrase inhibitors.
Bioorg Med Chem Lett 16: 4031-5 (2006)
Gilead Sciences
A gatekeeper residue for inhibitor sensitization of protein tyrosine phosphatases.
Bioorg Med Chem Lett 16: 4002-6 (2006)
Amherst College
Synthesis and biological activity of nociceptin/orphanin FQ(1-13)NH2 analogues modified in 9 and/or 13 position.
Bioorg Med Chem Lett 16: 4071-4 (2006)
University of Chemical Technology and Metallurgy
Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.
Bioorg Med Chem Lett 16: 4036-40 (2006)
Celera
Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase.
Bioorg Med Chem Lett 16: 4026-30 (2006)
Mrl Rome
5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity.
Bioorg Med Chem Lett 16: 4021-5 (2006)
Università
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold.
Bioorg Med Chem Lett 16: 4063-7 (2006)
University of Parma
Identification of metabolites of the tryptase inhibitor CRA-9249: observation of a metabolite derived from an unexpected hydroxylation pathway.
Bioorg Med Chem Lett 16: 4053-8 (2006)
Celera Genomics
Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
Bioorg Med Chem Lett 16: 4048-52 (2006)
Methylgene
Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors.
Bioorg Med Chem Lett 16: 3793-6 (2006)
Virginia Commonwealth University
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
NA
University of Newcastle upon Tyne
Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
J Biol Chem 281: 24818-30 (2006)
German Cancer Research Center
Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.
Bioorg Med Chem Lett 16: 3772-6 (2006)
Research Center Idrtech
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.
Bioorg Med Chem Lett 16: 3735-9 (2006)
Merck Research Laboratories
Dipeptide vinyl sultams: synthesis via the Wittig-Horner reaction and activity against papain, falcipain-2 and Plasmodium falciparum.
Bioorg Med Chem Lett 16: 4115-9 (2006)
University of Lisbon
Nepsilon-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine Nepsilon-deacetylation.
Bioorg Med Chem Lett 16: 3651-6 (2006)
University of Akron
Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.
Bioorg Med Chem Lett 16: 3657-62 (2006)
Glaxosmithkline
Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.
Bioorg Med Chem Lett 16: 3784-8 (2006)
Glaxosmithkline
Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
Bioorg Med Chem Lett 16: 4107-10 (2006)
Pharmacopeia Drug Discovery
New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A2B adenosine receptor antagonists.
Bioorg Med Chem Lett 16: 3642-5 (2006)
RhôNe-Poulenc Rorer
Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.
Bioorg Med Chem Lett 16: 3713-8 (2006)
Amgen
Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.
Bioorg Med Chem Lett 16: 3679-83 (2006)
Merck Research Laboratories
Design, synthesis, and SAR studies on a series of 2-pyridinylpiperazines as potent antagonists of the melanocortin-4 receptor.
Bioorg Med Chem Lett 16: 3693-6 (2006)
Neurocrine Biosciences
Privileged structure based ligands for melanocortin receptors--4,4-disubstituted piperidine derivatives.
Bioorg Med Chem Lett 16: 3843-6 (2006)
Eli Lilly
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
J Pharmacol Exp Ther 318: 772-81 (2006)
Eli Lilly
Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists.
Bioorg Med Chem Lett 16: 3674-8 (2006)
Schering-Plough Research Institute
BACE-1 inhibition by a series of psi[CH2NH] reduced amide isosteres.
Bioorg Med Chem Lett 16: 3635-8 (2006)
Merck Research Laboratories
Synthesis and structure-activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists.
Bioorg Med Chem Lett 16: 3668-73 (2006)
Schering-Plough Research Institute
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.
J Med Chem 49: 3012-8 (2006)
University of Bologna
Design and synthesis of substrate and intermediate analogue inhibitors of S-ribosylhomocysteinase.
J Med Chem 49: 3003-11 (2006)
The Ohio State University
Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase.
J Med Chem 49: 2998-3002 (2006)
The Scripps Research Institute
Synthesis and biological evaluation of glycosidase inhibitors: gem-difluoromethylenated nojirimycin analogues.
J Med Chem 49: 2989-97 (2006)
Chinese Academy of Sciences
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
J Med Chem 49: 2953-68 (2006)
Celera
Application of the Goldilocks effect to the design of potent and selective inhibitors of phenylethanolamine N-methyltransferase: balancing pKa and steric effects in the optimization of 3-methyl-1,2,3,4-tetrahydroisoquinoline inhibitors by beta-fluorination.
J Med Chem 49: 2939-52 (2006)
University of Kansas
New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives.
J Med Chem 49: 2909-20 (2006)
University of Wisconsin-Madison
Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies.
J Med Chem 49: 2898-908 (2006)
Boehringer Ingelheim Pharmaceuticals
NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties.
J Med Chem 49: 2886-97 (2006)
Università
Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain.
J Med Chem 49: 2876-85 (2006)
Mgi Pharma
Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
J Med Chem 49: 2868-75 (2006)
University of Arizona Tucson
2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.
J Med Chem 49: 2861-7 (2006)
Leiden/Amsterdam Center For Drug Research
The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding.
J Med Chem 49: 2858-60 (2006)
University of Washington
3-Substituted gem-cyclohexane sulfone based gamma-secretase inhibitors for Alzheimer's disease: conformational analysis and biological activity.
Bioorg Med Chem Lett 16: 3839-42 (2006)
Merck Sharp and Dohme Research Laboratories
Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
Bioorg Med Chem Lett 16: 3646-50 (2006)
Procter & Gamble Pharmaceuticals
Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
Bioorg Med Chem Lett 16: 3755-60 (2006)
Bristol-Myers Squibb
Synthesis of a potential photoactivatable anandamide analog.
Bioorg Med Chem Lett 16: 3765-8 (2006)
University of Montpellier
Cyclobutane derivatives as potent NK1 selective antagonists.
Bioorg Med Chem Lett 16: 3859-63 (2006)
Schering-Plough Research Institute
Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates.
Bioorg Med Chem Lett 16: 3813-6 (2006)
University of Tokyo
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.
Bioorg Med Chem Lett 16: 3706-12 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3 or 4.
Bioorg Med Chem Lett 16: 3688-92 (2006)
Lanzhou University
Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity.
Bioorg Med Chem Lett 16: 3376-9 (2006)
Institute For Medical Research
Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.
Bioorg Med Chem Lett 16: 3639-41 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor.
Bioorg Med Chem Lett 16: 3684-7 (2006)
Merck
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.
Bioorg Med Chem Lett 16: 3751-4 (2006)
Banyu Tsukuba Research Institute
Structure-guided design of peptide-based tryptase inhibitors.
Biochemistry 45: 5964-73 (2006)
Celera
Design of cyclic peptides with agonist activity at melanocortin receptor-4.
Bioorg Med Chem Lett 16: 3723-6 (2006)
Asahi Kasei Pharma
3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.
Bioorg Med Chem Lett 16: 3789-92 (2006)
Chiron
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
Bioorg Med Chem Lett 16: 3740-4 (2006)
Abbott Laboratories
Nanomolar inhibition of the enterobactin biosynthesis enzyme, EntE: synthesis, substituent effects, and additivity.
Bioorg Med Chem Lett 16: 3802-5 (2006)
University of North Carolina
Array synthesis of progesterone receptor antagonists: 3-aryl-1,2-diazepines.
Bioorg Med Chem Lett 16: 3777-9 (2006)
Glaxosmithkline
Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists.
Bioorg Med Chem Lett 16: 3371-5 (2006)
National Institute On Drug Abuse
Synthesis and SAR of novel histamine H3 receptor antagonists.
Bioorg Med Chem Lett 16: 3415-8 (2006)
Eli Lilly
Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase.
Bioorg Med Chem Lett 16: 3809-12 (2006)
Cardiff University
Arylpiperazines with N-acylated amino acids as 5-HT1A receptor ligands.
Bioorg Med Chem Lett 16: 3406-10 (2006)
University of Montpellier
Strategy for discovering chemical inhibitors of human cyclophilin a: focused library design, virtual screening, chemical synthesis and bioassay.
J Comb Chem 8: 326-37 (2006)
East China Univesity of Science and Technology
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
J Pharmacol Exp Ther 318: 657-65 (2006)
Wyeth Research
Bivalent inhibitors of glutathione S-transferase: the effect of spacer length on isozyme selectivity.
Bioorg Med Chem Lett 16: 3780-3 (2006)
Syntrix Biosytems
Inhibition of chloroplast electron transport reactions by trifluralin and diallate.
Plant Physiol 60: 840-4 (1977)
The University of Michigan
Efforts toward oral bioavailability in factor VIIa inhibitors.
Bioorg Med Chem Lett 16: 3829-32 (2006)
Celera
A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
Bioorg Med Chem Lett 16: 3609-13 (2006)
Kaist
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.
Bioorg Med Chem Lett 16: 3833-8 (2006)
Abbott Laboratories
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides.
Bioorg Med Chem Lett 16: 3367-70 (2006)
Abbott Laboratories
Privileged structure based ligands for melanocortin-4 receptors--aliphatic piperazine derivatives.
Bioorg Med Chem Lett 16: 3449-53 (2006)
Eli Lilly
Synthesis and SAR of 1,3-disubstituted cyclohexylmethyl urea and amide derivatives as non-peptidic motilin receptor antagonists.
Bioorg Med Chem Lett 16: 3362-6 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
Bioorg Med Chem Lett 16: 3605-8 (2006)
RhôNe-Poulenc Rorer
Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
Bioorg Med Chem Lett 16: 3463-8 (2006)
Johnson & Johnson Pharmaceutical
Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.
Bioorg Med Chem Lett 16: 3614-7 (2006)
Arpida
Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
Bioorg Med Chem Lett 16: 3424-9 (2006)
Abbott Laboratories
Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3.
Bioorg Med Chem Lett 16: 3419-23 (2006)
Université
Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors.
Bioorg Med Chem Lett 16: 3484-8 (2006)
Chugai Pharma
Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4.
Bioorg Med Chem Lett 16: 3504-9 (2006)
Millennium Pharmaceuticals
Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.
Bioorg Med Chem Lett 16: 3434-9 (2006)
Celera Genomics
Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
Bioorg Med Chem Lett 16: 3459-62 (2006)
Ambrilia Biopharma
Sundaicumones A and B, polyprenylated acylphloroglucinol derivatives from Calophyllumsundaicum with weak activity against the glucocorticoid receptor.
J Nat Prod 69: 707-9 (2006)
Merlion Pharmaceuticals
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
J Nat Prod 69: 700-3 (2006)
University of Illinois At Chicago
Vanillic acid glycoside and quinic acid derivatives from Gardeniae Fructus.
J Nat Prod 69: 600-3 (2006)
Korea Institute of Science and Technology
Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells.
J Nat Prod 69: 547-52 (2006)
University of Mississippi
Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis.
J Nat Prod 69: 536-41 (2006)
University of Illinois At Chicago
Synthesis of biphenyltrienes as probes for beta-amyloid plaques.
J Med Chem 49: 2841-4 (2006)
University of Pennsylvania
Biological evaluation of bishydroxymethyl-substituted cage dimeric 1,4-dihydropyridines as a novel class of p-glycoprotein modulating agents in cancer cells.
J Med Chem 49: 2838-40 (2006)
Martin-Luther-University Halle-Wittenberg
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
J Med Chem 49: 2784-93 (2006)
Takeda Pharmaceutical
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
J Med Chem 49: 2758-71 (2006)
Glaxosmithkline
Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.
J Med Chem 49: 2750-7 (2006)
Schering-Plough Research Institute
Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX.
J Med Chem 49: 2743-9 (2006)
University of Namur
[2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
J Med Chem 49: 2735-42 (2006)
National Institute of Radiological Sciences
Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains.
J Med Chem 49: 2725-30 (2006)
Nagasaki University
Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
J Med Chem 49: 2703-12 (2006)
National Health Research Institutes
Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists.
J Med Chem 49: 2689-702 (2006)
National Institute of Diabetes and Digestive and Kidney Diseases
Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.
J Med Chem 49: 2681-8 (2006)
Kyoto University
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
J Med Chem 49: 2673-6 (2006)
University of Illinois At Chicago
Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).
J Med Chem 49: 2669-72 (2006)
Millennium Pharmaceuticals
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.
Chem Biol 13: 261-8 (2006)
Academia Sinica
Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Biochemistry 45: 5468-77 (2006)
Johnson & Johnson Pharmaceutical
Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists.
Bioorg Med Chem Lett 16: 3444-8 (2006)
Pfizer
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Bioorg Med Chem Lett 16: 3096-100 (2006)
Johnson & Johnson Pharmaceutical Research and Development
The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.
Bioorg Med Chem Lett 16: 3489-94 (2006)
Merck Research Laboratories
Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Bioorg Med Chem Lett 16: 3510-3 (2006)
Procter and Gamble Pharmaceuticals
3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor.
Bioorg Med Chem Lett 16: 3524-8 (2006)
Johnson & Johnson Pharmaceutical Research and Development
A new class of selective, non-basic 5-HT2A receptor antagonists.
Bioorg Med Chem Lett 16: 3201-4 (2006)
Merck Sharp & Dohme
Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties.
Bioorg Med Chem Lett 16: 3574-7 (2006)
Abbott Laboratories
Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
Bioorg Med Chem Lett 16: 3430-3 (2006)
Genomics Institute of The Novartis Research Foundation
Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides.
Bioorg Med Chem Lett 16: 3533-6 (2006)
Astrazeneca
Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists.
Bioorg Med Chem Lett 16: 3115-20 (2006)
Johnson & Johnson Pharmaceutical
Development of lipopeptides for inhibiting 20S proteasomes.
Bioorg Med Chem Lett 16: 3277-81 (2006)
Cnrs-Université
The discovery of tropane-derived CCR5 receptor antagonists.
Chem Biol Drug Des 67: 305-8 (2006)
TBA
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
NA
Japanese Foundation for Cancer Research
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity.
Bioorg Med Chem 14: 5357-69 (2006)
F. Hoffmann-La Roche
Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.
Bioorg Med Chem 14: 4740-9 (2006)
Abbott Laboratories
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring.
Bioorg Med Chem Lett 16: 3170-4 (2006)
The University of Iowa
Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
Bioorg Med Chem Lett 16: 3541-4 (2006)
University of Siena
Phosphonic acid-containing analogues of mycophenolic acid as inhibitors of IMPDH.
Bioorg Med Chem Lett 16: 3479-83 (2006)
Gilead Sciences
Novel 5-azaindole factor VIIa inhibitors.
Bioorg Med Chem Lett 16: 3197-200 (2006)
Celera
Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists.
Bioorg Med Chem Lett 16: 3569-73 (2006)
Banyu Tsukuba Research Institute
Synthesis of Hsp90 dimerization modulators.
Bioorg Med Chem Lett 16: 3529-32 (2006)
Memorial Sloan-Kettering Cancer Center
2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors.
Bioorg Med Chem Lett 16: 3564-8 (2006)
Merck Research Laboratories
2,3,7-Trisubstituted pyrazolo[1,5-d][1,2,4]triazines: functionally selective GABAA alpha3-subtype agonists.
Bioorg Med Chem Lett 16: 3550-4 (2006)
Merck Sharp and Dohme Research Laboratories
Function of the alkyl side chains of Deltalac-acetogenins in the inhibitory effect on mitochondrial complex I (NADH-ubiquinone oxidoreductase).
Bioorg Med Chem Lett 16: 3555-8 (2006)
Kyoto University
Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.
Bioorg Med Chem Lett 16: 3219-23 (2006)
Florida A&M University
Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions.
Bioorg Med Chem Lett 16: 3139-43 (2006)
Universita Degli Studi Di Firenze
Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.
Bioorg Med Chem Lett 16: 3156-61 (2006)
Pfizer
Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease.
Bioorg Med Chem Lett 16: 3337-40 (2006)
Sunway University College
Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors.
J Am Chem Soc 128: 5310-1 (2006)
Purdue University
Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
Bioorg Med Chem Lett 16: 3213-8 (2006)
University of Tokyo
3,4-Fused cyclohexyl sulfones as gamma-secretase inhibitors.
Bioorg Med Chem Lett 16: 3073-7 (2006)
Neuroscience Research Centre
Novel alkylpolyaminoguanidines and alkylpolyaminobiguanides with potent antitrypanosomal activity.
Bioorg Med Chem Lett 16: 3229-32 (2006)
Wayne State University
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
Bioorg Med Chem Lett 16: 3209-12 (2006)
RhôNe-Poulenc Rorer
Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor.
Bioorg Med Chem Lett 16: 3162-5 (2006)
Novo Nordisk
A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.
Bioorg Med Chem Lett 16: 3205-8 (2006)
Nerviano Medical Sciences
Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
Bioorg Med Chem Lett 16: 3144-6 (2006)
Institut Curie
Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.
Chem Biol Drug Des 67: 206-14 (2006)
UniversitÀ
Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
Chem Biol Drug Des 67: 201-5 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity.
J Med Chem 49: 2661-5 (2006)
University of Cincinnati
Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors.
J Med Chem 49: 2656-60 (2006)
Ghent University
Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2alpha.
J Med Chem 49: 2611-20 (2006)
University of MüNster
A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
J Med Chem 49: 2600-10 (2006)
Merck Sharp & Dohme Research Laboratories
Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity.
J Med Chem 49: 2593-9 (2006)
University of Minnesota
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
J Med Chem 49: 2579-92 (2006)
University Walk
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists.
J Med Chem 49: 2568-78 (2006)
Abbott Laboratories
A chemical switch for the modulation of the functional activity of higher homologues of histamine on the human histamine H3 receptor: effect of various substitutions at the primary amino function.
J Med Chem 49: 2549-57 (2006)
Vrije Universiteit Amsterdam
4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore modeling.
J Med Chem 49: 2526-33 (2006)
Lund University
Refinement of the benzodiazepine receptor site topology by structure-activity relationships of new N-(heteroarylmethyl)indol-3-ylglyoxylamides.
J Med Chem 49: 2489-95 (2006)
University of Pisa
Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their"receptor desmodynamic processes".
J Med Chem 49: 2456-62 (2006)
University of Naples Federico Ii
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
J Med Chem 49: 2440-55 (2006)
Bristol-Myers Squibb
Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking.
J Med Chem 49: 2417-30 (2006)
Vrije Universiteit
Practical synthesis and evaluation of the biological activities of 1alpha,25-dihydroxyvitamin D3 antagonists, 1alpha,25-dihydroxyvitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis.
J Med Chem 49: 2398-406 (2006)
University of Tokyo
Slow-binding human serine racemase inhibitors from high-throughput screening of combinatorial libraries.
J Med Chem 49: 2388-97 (2006)
University of California
Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.
J Med Chem 49: 2363-6 (2006)
Università
Flexible synthesis and biological evaluation of novel 5-deoxyadenophorine analogues.
Bioorg Med Chem Lett 16: 3262-7 (2006)
Université
Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP.
Bioorg Med Chem Lett 16: 3175-9 (2006)
Merck Research Laboratories
Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Bioorg Med Chem Lett 16: 3150-5 (2006)
Abbott Laboratories
4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.
Bioorg Med Chem Lett 16: 3121-4 (2006)
Chiron
Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands.
Bioorg Med Chem Lett 16: 3233-7 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
Bioorg Med Chem Lett 16: 3595-9 (2006)
Chiron
P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors.
Bioorg Med Chem Lett 16: 3125-30 (2006)
University of Ferrara
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Bioorg Med Chem Lett 16: 3310-4 (2006)
Johnson & Johnson Pharmaceutical
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.
Org Lett 8: 1729-32 (2006)
The Scripps Research Institute
Selectivity and potency of cyclin-dependent kinase inhibitors.
AAPS J 8: 204-21 (2006)
Georgetown University
Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors.
Bioorg Med Chem Lett 16: 3268-72 (2006)
National Health Research Institutes
2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists.
Bioorg Med Chem Lett 16: 2905-8 (2006)
Merck Research Laboratories
Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
Bioorg Med Chem Lett 16: 3287-91 (2006)
Gsk
Diarylacetylene piperidinyl amides as novel anxiolytics.
Bioorg Med Chem Lett 16: 3065-7 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana.
Bioorg Med Chem Lett 16: 3273-6 (2006)
Korea Research Institute of Bioscience and Biotechnology
Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.
Bioorg Med Chem Lett 16: 3282-6 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.
Bioorg Med Chem 14: 4792-802 (2006)
Vernalis (R&D)
NK1 antagonists based on seven membered lactam scaffolds.
Bioorg Med Chem Lett 16: 2929-32 (2006)
Merck Sharp and Dohme Research Laboratories
Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease.
Bioorg Med Chem Lett 16: 3015-8 (2006)
Emory University
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
J Med Chem 49: 2339-52 (2006)
Abbott Laboratories
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
J Med Chem 49: 2333-8 (2006)
University of Piemonte Orientale
Development of the first potential covalent inhibitors of anandamide cellular uptake.
J Med Chem 49: 2320-32 (2006)
Institute of Biomolecular Chemistry
Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas.
J Med Chem 49: 2294-310 (2006)
Schering-Plough Research Institute
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors.
J Med Chem 49: 2268-75 (2006)
Washington University
Novel potent and efficacious nonpeptidic urotensin II receptor agonists.
J Med Chem 49: 2232-40 (2006)
G£Teborg University
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Pharmacol Rev 49: 2222-31 (2006)
Saarland University
Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
J Med Chem 49: 2210-21 (2006)
Glaxosmithkline
Identification of potent and selective inhibitors of PDGF receptor autophosphorylation.
J Med Chem 49: 2186-92 (2006)
Kirin Brewery
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
J Med Chem 49: 2174-85 (2006)
National Institutes of Health
Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity.
J Med Chem 49: 2166-73 (2006)
La Jolla Pharmaceutical
Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries.
J Med Chem 49: 2147-50 (2006)
Max Planck Research Unit For Enzymology of Protein Folding
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
J Med Chem 49: 2143-6 (2006)
Pharmaceutical Research Institute
Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish.
Nat Chem Biol 2: 265-73 (2006)
Dana-Farber Cancer Institute
Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype.
Bioorg Med Chem Lett 16: 2955-9 (2006)
Friedrich-Alexander University
Synthetic analogues of the manzamenones and plakoridines which inhibit DNA polymerase.
Bioorg Med Chem Lett 16: 2877-81 (2006)
University of Manchester
The search for novel TRPV1-antagonists: from carboxamides to benzimidazoles and indazolones.
Bioorg Med Chem Lett 16: 2872-6 (2006)
Merck Sharp & Dohme
A new non-azole inhibitor of ABA 8'-hydroxylase: effect of the hydroxyl group substituted for geminal methyl groups in the six-membered ring.
Bioorg Med Chem Lett 16: 3302-5 (2006)
Shizuoka University
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Bioorg Med Chem Lett 16: 2842-5 (2006)
Amgen
Two novel aromatic valerenane-type sesquiterpenes from the Chinese green alga Caulerpa taxifolia.
Bioorg Med Chem Lett 16: 2947-50 (2006)
Chinese Academy of Sciences
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
J Nat Prod 69: 432-5 (2006)
Tom'S of Maine
Bioactive dammarane triterpenes from the mangrove plant Bruguiera gymnorrhiza.
J Nat Prod 69: 421-4 (2006)
Mahidol University
N1-(3-cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a potent partial agonist for the human histamine H1- and H2-receptors.
J Pharmacol Exp Ther 317: 1262-8 (2006)
University of Kansas
Development of activity-based probes for trypsin-family serine proteases.
Bioorg Med Chem Lett 16: 2882-5 (2006)
Celera Genomics
A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors.
Bioorg Med Chem Lett 16: 2900-4 (2006)
Merck Research Laboratories
1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists.
Bioorg Med Chem Lett 16: 2969-73 (2006)
The Genomics Institute of The Novartis Research Foundation
Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
Bioorg Med Chem Lett 16: 2886-90 (2006)
Wroclaw University of Technology
Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Bioorg Med Chem Lett 16: 2920-4 (2006)
Bristol-Myers Squibb
Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
Bioorg Med Chem Lett 16: 2909-14 (2006)
Celera Genomics
Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase.
Bioorg Med Chem Lett 16: 2915-9 (2006)
China Pharmaceutical University
The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.
Bioorg Med Chem Lett 16: 2891-4 (2006)
Athersys
New 4-(4-methyl-phenyl)phthalazin-1(2H)-one derivatives and their effects on alpha1-receptors.
Bioorg Med Chem Lett 16: 2575-9 (2006)
Università
1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2alpha inhibitors.
Bioorg Med Chem Lett 16: 2978-81 (2006)
Wyeth Research
Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum.
Bioorg Med Chem Lett 16: 3061-4 (2006)
Korea Research Institute of Bioscience and Biotechnology
Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.
Bioorg Med Chem Lett 16: 2724-8 (2006)
Pharmacopeia Drug Discovery
Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.
Bioorg Med Chem Lett 16: 2986-90 (2006)
Mochida Pharmaceutical
Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
J Med Chem 49: 2138-42 (2006)
Eli Lilly
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
J Med Chem 49: 2117-26 (2006)
Kochi Medical School
Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.
J Med Chem 49: 2110-6 (2006)
Friedrich-Schiller-UniversitäT Jena
Synthesis and biological evaluation of purealin and analogues as cytoplasmic dynein heavy chain inhibitors.
J Med Chem 49: 2063-76 (2006)
University of Pittsburgh
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
J Med Chem 49: 2037-48 (2006)
Takeda Pharmaceutical
Branched diacylglycerol-lactones as potent protein kinase C ligands and alpha-secretase activators.
J Med Chem 49: 2028-36 (2006)
Research Institute of Pharmaceutical Sciences
Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
J Med Chem 49: 2022-7 (2006)
University of Kuopio
Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors.
J Med Chem 49: 1980-90 (2006)
Bar-Ilan University
Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.
J Med Chem 49: 1946-52 (2006)
University of Arizona
Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.
J Med Chem 49: 1939-45 (2006)
Sapienza University of Rome
Highly chiral muscarinic ligands: the discovery of (2S,2'R,3'S,5'R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M2 partial agonist.
J Med Chem 49: 1925-31 (2006)
University of Florence
A systematic study of C-glucoside trisphosphates as myo-inositol trisphosphate receptor ligands. Synthesis of beta-C-glucoside trisphosphates based on the conformational restriction strategy.
J Med Chem 49: 1900-9 (2006)
Hokkaido University
Synthesis, pharmacological evaluation, and molecular modeling studies of novel peptidic CAAX analogues as farnesyl-protein-transferase inhibitors.
J Med Chem 49: 1882-90 (2006)
Universita Di Napoli Federico Ii
Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
J Med Chem 49: 1867-73 (2006)
University of North Carolina at Chapel Hill
Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.
J Am Chem Soc 128: 3524-5 (2006)
University of Illinois At Urbana-Champaign
Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A.
Nat Chem Biol 2: 213-20 (2006)
Mcgill University
3-Amidoquinuclidine derivatives: synthesis of compounds and inhibition of butyrylcholinesterase.
Bioorg Chem 34: 90-8 (2006)
University of Zagreb
Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors.
Bioorg Med Chem Lett 16: 2996-9 (2006)
Korea Research Institute of Chemical Technology
High-throughput screening for Hsp90 ATPase inhibitors.
Bioorg Med Chem Lett 16: 3005-8 (2006)
The University of Kansas
SAR studies: designing potent and selective LXR agonists.
Bioorg Med Chem Lett 16: 3055-60 (2006)
Merck Research Laboratories
Identification of an indole series of prostaglandin D2 receptor antagonists.
Bioorg Med Chem Lett 16: 3043-8 (2006)
Merck Frosst Canada
5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists.
Bioorg Med Chem Lett 16: 2791-5 (2006)
Merck Research Laboratories
Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents.
Bioorg Med Chem Lett 16: 3039-42 (2006)
Pfizer
New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
Bioorg Med Chem Lett 16: 3034-8 (2006)
Nih
Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.
Bioorg Med Chem Lett 16: 2595-8 (2006)
Department of Medicinal Chemistry Merck
Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors.
Bioorg Med Chem Lett 16: 2590-4 (2006)
Abbott Laboratories
Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2.
Bioorg Med Chem Lett 16: 2689-92 (2006)
Genomics Institute of The Novartis Research Foundation
Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists.
Bioorg Med Chem Lett 16: 2621-7 (2006)
Millennium Pharmaceuticals
Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine.
Bioorg Med Chem Lett 16: 3049-54 (2006)
Daiichi Asubio Medical Research Laboratories
Virtual and biomolecular screening converge on a selective agonist for GPR30.
Nat Chem Biol 2: 207-12 (2006)
University of New Mexico Health Sciences Center
A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
J Biol Chem 281: 12445-50 (2006)
Duke University Medical Center
Synthesis and SAR studies of diarylpyrrole anticoccidial agents.
Bioorg Med Chem Lett 16: 2817-21 (2006)
Merck Research Laboratories
Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety.
Bioorg Med Chem Lett 16: 2641-7 (2006)
Abbott
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
Bioorg Med Chem Lett 16: 2672-6 (2006)
Astrazeneca
Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands.
Bioorg Med Chem Lett 16: 2654-7 (2006)
Université
Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.
Bioorg Med Chem Lett 16: 2608-12 (2006)
Merck Frosst Center For Therapeutic Research
A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.
Bioorg Med Chem Lett 16: 2632-6 (2006)
Novartis Institutes For Biomedical Research
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
Bioorg Med Chem Lett 16: 2753-7 (2006)
University of Wuerzburg
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.
Bioorg Med Chem Lett 16: 2699-704 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
N-Benzylbenzamides: a new class of potent tyrosinase inhibitors.
Bioorg Med Chem Lett 16: 2682-4 (2006)
Seoul National University
Vasorelaxant activity of phthalazinones and related compounds.
Bioorg Med Chem Lett 16: 2786-90 (2006)
Universidad De Salamanca
(R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis.
Bioorg Med Chem Lett 16: 2555-8 (2006)
Paradigm Therapeutics
Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
J Med Chem 49: 1828-32 (2006)
Uppsala University
Stereochemical sensitivity of the human UDP-glucuronosyltransferases 2B7 and 2B17.
J Med Chem 49: 1818-27 (2006)
University of Helsinki
Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior.
J Med Chem 49: 1808-17 (2006)
Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
J Med Chem 49: 1773-80 (2006)
University of Arizona
Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.
J Med Chem 49: 1766-72 (2006)
Niddk
Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
J Med Chem 49: 1754-65 (2006)
University of T£Bingen
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
J Med Chem 49: 1720-9 (2006)
University of Trieste
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.
J Med Chem 49: 1693-705 (2006)
P. Angeletti S.P.A. (Merck Research Laboratories)
Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors.
J Med Chem 49: 1684-92 (2006)
University of Houston
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
J Med Chem 49: 1668-83 (2006)
University of Alberta
Discovery of protein phosphatase 2C inhibitors by virtual screening.
J Med Chem 49: 1658-67 (2006)
Rockefeller University
Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.
J Med Chem 49: 1613-23 (2006)
Shanghai Institutes For Biological Sciences
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
J Med Chem 49: 1597-612 (2006)
Gsk
Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
J Med Chem 49: 1585-96 (2006)
Graduate School of The Chinese Academy of Sciences
Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.
J Med Chem 49: 1576-84 (2006)
University of Mississippi
Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
J Med Chem 49: 1562-75 (2006)
Roche Palo Alto
Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
J Med Chem 49: 1549-61 (2006)
Università
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
J Med Chem 49: 1517-25 (2006)
Chugai Pharma Usa
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.
J Med Chem 49: 1506-8 (2006)
Central Pharmaceutical Research Institute
Selective irreversible inhibition of fructose 1,6-bisphosphate aldolase from Trypanosoma brucei.
J Med Chem 49: 1499-502 (2006)
Université
Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with "two-prong" inhibitors reveal the molecular basis of high affinity.
J Am Chem Soc 128: 3011-8 (2006)
University of Pennsylvania
Synthesis of a potent 5'-methylthioadenosine/S-adenosylhomocysteine (MTAN) inhibitor.
Bioorg Med Chem Lett 16: 2662-5 (2006)
Biocryst Pharmaceuticals
Studies on the novel alpha-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues.
Bioorg Med Chem Lett 16: 2710-3 (2006)
Zhengzhou University
Synthesis of phospholipase A2 inhibitory biflavonoids.
Bioorg Med Chem Lett 16: 2373-5 (2006)
Kangwon National University
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Bioorg Med Chem Lett 16: 2729-33 (2006)
Osi Pharmaceuticals
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.
Bioorg Med Chem Lett 16: 2705-9 (2006)
Astrazeneca R&D
Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant.
Bioorg Med Chem Lett 16: 2748-52 (2006)
Mrl Rome
Discovery of novel biaryl heterocyclic EP1 receptor antagonists.
Bioorg Med Chem Lett 16: 2666-71 (2006)
Glaxosmithkline
Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents.
Bioorg Med Chem Lett 16: 2719-23 (2006)
Central Drug Research Institute
Bioactive compounds from Peperomia pellucida.
J Nat Prod 69: 247-50 (2006)
Chinese Academy of Sciences
N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.
Bioorg Med Chem Lett 16: 2714-8 (2006)
Eli Lilly
Optimization of 2-aminothiazole derivatives as CCR4 antagonists.
Bioorg Med Chem Lett 16: 2800-3 (2006)
Amgen
Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent.
Bioorg Med Chem 14: 4208-16 (2006)
Johnson & Johnson Pharmaceutical
Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2.
Bioorg Med Chem Lett 16: 2777-80 (2006)
Universite Paris 5 René
An efficient rapid system for profiling the cellular activities of molecular libraries.
Proc Natl Acad Sci U S A 103: 3153-8 (2006)
Genomics Institute of The Novartis Research Foundation
Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
Chem Biol 13: 201-11 (2006)
Cyclacel
Structure-based optimization of MurF inhibitors.
Chem Biol Drug Des 67: 58-65 (2006)
Abbott Laboratories
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Chem Biol Drug Des 67: 46-57 (2006)
Ariad Pharmaceuticals
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.
Bioorg Med Chem Lett 16: 2416-8 (2006)
University of Virginia
Discovery of novel hydroxy pyrazole based factor IXa inhibitor.
Bioorg Med Chem Lett 16: 2796-9 (2006)
Celera Genomics
Identification of potent phenyl imidazoles as opioid receptor agonists.
Bioorg Med Chem Lett 16: 2505-8 (2006)
Johnson & Johnson Pharmaceutical Research & Development
Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships.
Bioorg Med Chem Lett 16: 2539-42 (2006)
Ucb Pharma
Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Bioorg Med Chem Lett 16: 2419-22 (2006)
Glaxosmithkline
Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
Bioorg Med Chem Lett 16: 2170-2 (2006)
Naresuan University
Low molecular weight indole fragments as IMPDH inhibitors.
Bioorg Med Chem Lett 16: 2535-8 (2006)
Ucb Pharma
Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres.
Bioorg Med Chem Lett 16: 2380-6 (2006)
Kyoto Pharmaceutical University
Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Bioorg Med Chem Lett 16: 2411-5 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Structure-activity relationship of thiopyrimidines as mGluR5 antagonists.
Bioorg Med Chem Lett 16: 2467-9 (2006)
Nps Pharmaceuticals
Fluorescent glycosidase inhibiting 1,5-dideoxy-1,5-iminoalditols.
Bioorg Med Chem Lett 16: 2067-70 (2006)
Technische UniversitäT Graz
Ketopiperazine-based renin inhibitors: optimization of the "C" ring.
Bioorg Med Chem Lett 16: 2500-4 (2006)
Pfizer
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Bioorg Med Chem Lett 16: 1869-73 (2006)
Purdue University
Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Bioorg Med Chem Lett 16: 2532-4 (2006)
Wyeth Research
Dipeptide nitrile inhibitors of cathepsin K.
Bioorg Med Chem Lett 16: 2549-54 (2006)
Novartis Pharmaceuticals
4-Amino derivatives of the Hsp90 inhibitor CCT018159.
Bioorg Med Chem Lett 16: 2543-8 (2006)
Vernalis
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
J Med Chem 49: 1475-85 (2006)
Pfizer
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
J Med Chem 49: 1455-65 (2006)
Glsynthesis
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.
J Med Chem 49: 1433-41 (2006)
Institute of Medical Research Biotechnology Centre
1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.
J Med Chem 49: 1420-32 (2006)
Organix
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
J Med Chem 49: 1413-9 (2006)
The Ohio State University
Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology.
J Med Chem 49: 1388-96 (2006)
The Danish University of Pharmaceutical Sciences
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
J Med Chem 49: 1379-87 (2006)
Georgia State University
Novel human lipoxygenase inhibitors discovered using virtual screening with homology models.
J Med Chem 49: 1356-63 (2006)
University of California
Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors.
J Med Chem 49: 1346-55 (2006)
Astex
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
J Med Chem 49: 1325-45 (2006)
University of Bath
Vitamin D receptor: ligand recognition and allosteric network.
J Med Chem 49: 1313-24 (2006)
Tokyo Medical and Dental University
Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
J Med Chem 49: 1282-90 (2006)
University of Glasgow
Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
J Med Chem 49: 1271-81 (2006)
Johannes Gutenberg University
Dual binding mode of a novel series of DHODH inhibitors.
J Med Chem 49: 1239-47 (2006)
4Sc
Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
J Med Chem 49: 1235-8 (2006)
TBA
Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.
J Med Chem 49: 1231-4 (2006)
TBA
1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b.
J Med Chem 49: 1227-30 (2006)
TBA
Inactivation of S-adenosyl-L-homocysteine hydrolase by 6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine and 6'-chloro-6'-cyano-5',6'-didehydro-6'-deoxyhomoadenosine. Antiviral and cytotoxic effects.
J Med Chem 49: 1223-6 (2006)
TBA
Inhibition of S/G2 phase CDK4 reduces mitotic fidelity.
J Biol Chem 281: 9987-95 (2006)
University of Queensland
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
Bioorg Med Chem Lett 16: 2357-63 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
J Pharmacol Exp Ther 317: 910-8 (2006)
Acadia Pharmaceuticals
Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan derivatives.
Bioorg Med Chem Lett 16: 2163-9 (2006)
Jacobus Pharmaceutical
Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability.
Bioorg Med Chem Lett 16: 2437-40 (2006)
University of Kuopio
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.
BMC Chem Biol 6: 1 (2006)
University of New Mexico
Synthesis and SAR studies of very potent imidazopyridine antiprotozoal agents.
Bioorg Med Chem Lett 16: 2479-83 (2006)
Merck Research Laboratories
Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors.
Bioorg Med Chem Lett 16: 2076-80 (2006)
Veterinary Medicine Research and Development Pfizer
Structure-activity relationship study between Ornithyl-Proline and Lysyl-Proline based tripeptidomimics as angiotensin-converting enzyme inhibitors.
Bioorg Med Chem Lett 16: 2117-21 (2006)
Institute of Genomics and Integrative Biology
The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor.
Bioorg Med Chem Lett 16: 2525-7 (2006)
Pfizer
Substituted coumarins as potent 5-lipoxygenase inhibitors.
Bioorg Med Chem Lett 16: 2528-31 (2006)
Merck Frosst Centre For Therapeutic Research
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
Bioorg Med Chem Lett 16: 2071-5 (2006)
Amgen
Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase.
Bioorg Med Chem Lett 16: 2518-21 (2006)
State University of New York-Esf
Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.
Bioorg Med Chem Lett 16: 1950-3 (2006)
Hoffmann-La Roche
Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety.
Bioorg Med Chem Lett 16: 2648-53 (2006)
Abbott
Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3.
Bioorg Med Chem Lett 16: 2091-4 (2006)
Glaxosmithkline
Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
Bioorg Med Chem Lett 16: 1913-9 (2006)
Chemical Diversity
A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.
Bioorg Med Chem Lett 16: 2200-4 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
Bioorg Med Chem Lett 16: 2158-62 (2006)
Cephalon
Discovery of novel heterocyclic factor VIIa inhibitors.
Bioorg Med Chem Lett 16: 2270-3 (2006)
Celera
Synthesis of novel benzofuran isoxazolines as protein tyrosine phosphatase 1B inhibitors.
Bioorg Med Chem Lett 16: 2139-43 (2006)
Central Drug Research Institute
Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
Placenta 27: 1096-102 (2006)
Hospital For Sick Children
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
Bioorg Med Chem Lett 16: 2182-8 (2006)
Kochi Medical School
Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents.
Bioorg Med Chem Lett 16: 2283-92 (2006)
University of Michigan
Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series.
Bioorg Med Chem Lett 16: 2095-100 (2006)
Bristol-Myers Squibb
The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors.
Bioorg Med Chem Lett 16: 2209-12 (2006)
Johnson and Johnson Pharmaceutical Research and Development
Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists.
Bioorg Med Chem Lett 16: 2302-5 (2006)
Millennium Pharmaceuticals
Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.
Bioorg Med Chem Lett 16: 2224-8 (2006)
Celera Genomics
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Bioorg Med Chem Lett 16: 1788-94 (2006)
Glaxosmithkline
Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.
Bioorg Med Chem Lett 16: 2101-4 (2006)
Columbia University College of Physicians and Surgeons
Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1.
Bioorg Med Chem Lett 16: 2173-6 (2006)
Genomics Institute of The Novartis Research Foundation
Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds.
Bioorg Med Chem Lett 16: 2260-5 (2006)
Astrazeneca
3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Bioorg Med Chem Lett 16: 1821-7 (2006)
The M.S. University of Baroda
An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
Bioorg Med Chem Lett 16: 2205-8 (2006)
Glaxosmithkline
Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole.
Bioorg Med Chem Lett 16: 1859-63 (2006)
Central Pharmaceutical Research Institute
Factor VIIa inhibitors: improved pharmacokinetic parameters.
Bioorg Med Chem Lett 16: 2243-6 (2006)
Celera Genomics
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Bioorg Med Chem Lett 16: 2219-23 (2006)
Merck Research Laboratories
Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
Bioorg Med Chem Lett 16: 2256-9 (2006)
Glaxosmithkline
Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
J Med Chem 49: 1212-6 (2006)
National Health Research Institutes
Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands.
J Med Chem 49: 1202-6 (2006)
Pfizer
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
J Med Chem 49: 1165-81 (2006)
Abbott Laboratories
A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins.
J Med Chem 49: 1149-56 (2006)
University of Santiago De Compostela
Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
J Med Chem 49: 1125-39 (2006)
Pfizer
New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
J Med Chem 49: 1113-7 (2006)
Ben-Gurion University of The Negev
Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues.
J Med Chem 49: 1101-12 (2006)
University of California San Francisco
Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications.
J Med Chem 49: 1080-100 (2006)
University of Illinois At Chicago
Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
J Med Chem 49: 1066-79 (2006)
Merck Frosst Centre For Therapeutic Research
Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
J Med Chem 49: 1055-65 (2006)
Duquesne University
SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.
J Med Chem 49: 1034-46 (2006)
Amgen
Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation.
J Med Chem 49: 1016-22 (2006)
Cardiff University
Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.
J Med Chem 49: 1006-15 (2006)
Chembridge Research Laboratories and Chembridge
Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
J Med Chem 49: 995-1005 (2006)
Schering-Plough Research Institute
3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
J Med Chem 49: 971-83 (2006)
Glaxosmithkline
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
J Med Chem 49: 955-70 (2006)
Astrazeneca
Evaluation of carbon-11-labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-iodoethenyl)phenyl]nortropane as a potential radioligand for imaging the serotonin transporter by PET.
J Med Chem 49: 942-6 (2006)
Emory University
Structural Insight into the Stereoselective Inhibition of MMP-8 by Enantiomeric Sulfonamide Phosphonates.
J Med Chem 49: 923-31 (2006)
Istituto Di Cristallografia
Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for receptor activation.
J Med Chem 49: 911-22 (2006)
Millennium Pharmaceuticals
Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A.
J Med Chem 49: 900-10 (2006)
University of Montpellier
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
J Med Chem 49: 892-9 (2006)
Instituto Venezolano De Investigaciones CientíFicas
Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
J Med Chem 49: 872-82 (2006)
University of Louvain
Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.
J Med Chem 49: 864-71 (2006)
Johann Wolfgang Goethe University
Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
J Med Chem 49: 850-63 (2006)
Mayo Clinic
Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.
J Med Chem 49: 847-9 (2006)
Banyu Tsukuba Research Institute
A selective estrogen receptor modulator for the treatment of hot flushes.
J Med Chem 49: 843-6 (2006)
Eli Lilly
Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
J Med Chem 49: 839-42 (2006)
Sunesis
Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase.
Bioorg Med Chem Lett 16: 1807-10 (2006)
Abbott Laboratories
Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
Bioorg Med Chem Lett 16: 1975-80 (2006)
Gnf
Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.
Bioorg Med Chem Lett 16: 2293-8 (2006)
Abbott Laboratories
Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
Bioorg Med Chem Lett 16: 2247-51 (2006)
Chiron
Global effects of the energetics of coenzyme binding: NADPH controls the protein interaction properties of human cytochrome P450 reductase.
Biochemistry 45: 1421-34 (2006)
Merck Research Laboratories
Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats.
Bioorg Med Chem Lett 16: 1799-802 (2006)
Pfizer
Novel non-benzimidazole chk2 kinase inhibitors.
Bioorg Med Chem Lett 16: 1924-8 (2006)
Johnson and Johnson Pharmaceutical Research and Development
Hydantoin derivatives as non-peptidic inhibitors of Ras farnesyl transferase.
Bioorg Med Chem Lett 16: 1954-6 (2006)
Keimyung University
Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: side chain exploration.
Bioorg Med Chem Lett 16: 1864-8 (2006)
Abbott Laboratories
Isoflavonoids with antiestrogenic activity from Millettia pachycarpa.
J Nat Prod 69: 138-41 (2006)
Meijo University
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
J Nat Prod 69: 107-12 (2006)
The University of Iowa
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.
J Nat Prod 69: 14-7 (2006)
Griffith University
Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
Bioorg Med Chem 14: 3438-46 (2006)
Kyushu Institute of Technology
Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.
Bioorg Med Chem Lett 16: 1934-7 (2006)
Abbott
Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors.
Bioorg Med Chem Lett 16: 1888-91 (2006)
Ghent University
Beta-diketo acids with purine nucleobase scaffolds: novel, selective inhibitors of the strand transfer step of HIV integrase.
Bioorg Med Chem Lett 16: 1920-3 (2006)
University of Georgia
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
Bioorg Med Chem Lett 16: 1775-9 (2006)
Merck Research Laboratories
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
Bioorg Med Chem Lett 16: 1780-3 (2006)
Merck Research Laboratories
First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
Bioorg Med Chem Lett 16: 1834-9 (2006)
Ucb Pharma
Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists.
Bioorg Med Chem Lett 16: 1892-7 (2006)
F. Hoffmann-La Roche
Synthesis and activity of small molecule GPR40 agonists.
Bioorg Med Chem Lett 16: 1840-5 (2006)
Glaxosmithkline Research and Development
Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
J Pharmacol Exp Ther 317: 562-70 (2006)
Meiji Seika Kaisha
Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
Mol Pharmacol 69: 1499-505 (2006)
Wake Forest University School of Medicine
Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
Bioorg Med Chem Lett 16: 1795-8 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinities.
Bioorg Med Chem Lett 16: 1938-40 (2006)
Johann Wolfgang Goethe-UniversitäT
Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases.
Bioorg Med Chem Lett 16: 1905-8 (2006)
Graduate School of Chinese Academy of Sciences
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.
Bioorg Med Chem Lett 16: 1740-3 (2006)
Abc Pharma
Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Bioorg Med Chem Lett 16: 1605-9 (2006)
Wyeth Research
Orally active purine-based inhibitors of the heat shock protein 90.
J Med Chem 49: 817-28 (2006)
Conforma Therapeutics
Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts.
J Med Chem 49: 811-6 (2006)
The University of Sydney
Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.
J Med Chem 49: 800-5 (2006)
University College London
Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents.
J Med Chem 49: 789-99 (2006)
Université
Dopamine/serotonin receptor ligands. 10: SAR Studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist.
J Med Chem 49: 760-9 (2006)
University of Bonn
Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids.
J Med Chem 49: 748-59 (2006)
Saarland University
(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.
J Med Chem 49: 716-26 (2006)
Astellas Pharma
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.
J Med Chem 49: 684-92 (2006)
Bryn Mawr College
Discovery of two novel, small-molecule inhibitors of DNA methylation.
J Med Chem 49: 678-83 (2006)
Polish Academy of Sciences
The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship.
J Med Chem 49: 664-77 (2006)
Probiodrug
Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
J Med Chem 49: 637-47 (2006)
Neurocrine Biosciences
Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor.
J Med Chem 49: 616-24 (2006)
University of Leipzig
Trisubstituted acridines as G-quadruplex telomere targeting agents. Effects of extensions of the 3,6- and 9-side chains on quadruplex binding, telomerase activity, and cell proliferation.
J Med Chem 49: 582-99 (2006)
University of London
Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
J Med Chem 49: 567-74 (2006)
Schering-Plough Research Institute
3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
J Med Chem 49: 554-66 (2006)
University of Kuopio
Classification of chemical compounds by protein-compound docking for use in designing a focused library.
J Med Chem 49: 523-33 (2006)
National Institute of Advanced Industrial Science and Technology (Aist)
Metal-mediated inhibition of Escherichia coli methionine aminopeptidase: structure-activity relationships and development of a novel scoring function for metal-ligand interactions.
J Med Chem 49: 511-22 (2006)
Saarland University
Computational study of antagonist/alpha1A adrenoceptor complexes--observations of conformational variations on the formation of ligand/receptor complexes.
J Med Chem 49: 501-10 (2006)
University of Dublin
Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
J Med Chem 49: 471-4 (2006)
Novartis Institutes For Biomedical Research
Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.
J Med Chem 49: 459-62 (2006)
Instituto De Quimica Medica (Csic)
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
J Med Chem 49: 456-8 (2006)
Chinese Academy of Sciences
HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.
J Med Chem 49: 445-7 (2006)
University of Georgia
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
J Med Chem 49: 441-4 (2006)
Array Biopharma
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Nat Chem Biol 2: 95-102 (2006)
Genomics Institute of The Novartis Research Foundation
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
Nat Chem Biol 2: 103-9 (2006)
Harvard University
Factor VIIa inhibitors: gaining selectivity within the trypsin family.
Bioorg Med Chem Lett 16: 1596-600 (2006)
Celera
1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
Bioorg Med Chem Lett 16: 2008-12 (2006)
Merck Sharp & Dohme Research Laboratories
Investigation of mechanism-based thrombin inhibitors: Implications of a highly conserved water molecule for the binding of coumarins within the S pocket.
Bioorg Med Chem Lett 16: 2017-21 (2006)
University of Namur
Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Bioorg Med Chem Lett 16: 2000-7 (2006)
Abbott Laboratories
Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter.
Bioorg Med Chem Lett 16: 2022-5 (2006)
Eli Lilly
Identification of a potent and selective non-basic cathepsin K inhibitor.
Bioorg Med Chem Lett 16: 1985-9 (2006)
Merck Frosst Centre For Therapeutic Research
In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.
Bioorg Med Chem Lett 16: 1969-74 (2006)
Molsoft
Small molecule inhibitors of plasma kallikrein.
Bioorg Med Chem Lett 16: 2034-6 (2006)
Celera Genomics
Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
Bioorg Med Chem Lett 16: 1628-32 (2006)
Schering-Plough Research Institute
6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Bioorg Med Chem Lett 16: 1468-72 (2006)
Merck Research Laboratories
Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594.
Bioorg Med Chem Lett 16: 2013-6 (2006)
Peking University
Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Bioorg Med Chem Lett 16: 1643-6 (2006)
Imclone Systems
A novel series of urea-based peptidomimetic calpain inhibitors.
Bioorg Med Chem Lett 16: 1965-8 (2006)
The University of Tennessee Health Science Center
Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Bioorg Med Chem Lett 16: 1486-90 (2006)
Gnf
Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.
Bioorg Med Chem Lett 16: 2037-41 (2006)
Celera Genomics
BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline.
Bioorg Med Chem Lett 16: 1995-9 (2006)
University of The Mediterranean
Allosteric control of an ionotropic glutamate receptor with an optical switch.
Nat Chem Biol 2: 47-52 (2006)
University of California Berkeley
Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro.
Nat Chem Biol 2: 39-46 (2006)
Harvard Medical School
Purmorphamine activates the Hedgehog pathway by targeting Smoothened.
Nat Chem Biol 2: 29-30 (2006)
Stanford University School of Medicine
Host sphingolipid biosynthesis as a target for hepatitis C virus therapy.
Nat Chem Biol 1: 333-7 (2006)
Chugai Pharmaceutical
Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.
Nat Chem Biol 1: 143-5 (2005)
Ludwig-Maximillians University of Munich
Assignment of protein function in the postgenomic era.
Nat Chem Biol 1: 130-42 (2006)
The Scripps Research Institute
Linking agonist binding to histamine H1 receptor activation.
Nat Chem Biol 1: 98-103 (2006)
Vrije Universiteit Amsterdam
Diversity-oriented synthesis: exploring the intersections between chemistry and biology.
Nat Chem Biol 1: 74-84 (2006)
Memorial Sloan-Kettering Cancer Center
Activity-based probes that target diverse cysteine protease families.
Nat Chem Biol 1: 33-8 (2005)
Stanford University
Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis.
Nat Chem Biol 1: 29-32 (2006)
Weill Medical College of Cornell University
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
J Biol Chem 281: 8010-5 (2006)
Merck Frosst Center For Therapeutic Research
Effector-repressor interactions, binding of a single effector molecule to the operator-bound TtgR homodimer mediates derepression.
J Biol Chem 281: 7102-9 (2006)
Estacion Experimental Del Zaidin
Herbicide-binding sites revealed in the structure of plant acetohydroxyacid synthase.
Proc Natl Acad Sci U S A 103: 569-73 (2006)
University of Queensland
Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Bioorg Med Chem Lett 16: 1610-5 (2006)
Cornell University
Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands.
Bioorg Med Chem Lett 16: 1175-9 (2006)
Merck Sharp and Dohme Research Laboratories
Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
Bioorg Med Chem Lett 16: 1679-85 (2006)
Abbott Laboratories
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
J Med Chem 49: 407-16 (2006)
Institute of Cancer Research
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
J Med Chem 49: 381-90 (2006)
Memorial Sloan-Kettering Cancer Center
2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
J Med Chem 49: 373-80 (2006)
National Health Research Institutes
Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors.
J Med Chem 49: 366-72 (2006)
University of Milan
Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.
J Med Chem 49: 358-65 (2006)
Università
Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes.
J Med Chem 49: 329-33 (2006)
Umr-Cnrs 5063
1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
J Med Chem 49: 318-28 (2006)
Alcon Research
Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.
J Med Chem 49: 282-99 (2006)
University of Bari Aldo Moro
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor.
J Med Chem 49: 273-81 (2006)
Ewha Womans University
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
J Med Chem 49: 256-62 (2006)
Harvard Medical School
Effect of polyamine homologation on the transport and biological properties of heterocyclic amidines.
J Med Chem 49: 232-45 (2006)
University of Rennes 1
Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
J Med Chem 49: 215-23 (2006)
University of Illinois At Urbana-Champaign
Rational design and enantioselective synthesis of (1R,4S,5R,6S)-3-azabicyclo[3.3.0]octane-4,6-dicarboxylic acid - a novel inhibitor at human glutamate transporter subtypes 1, 2, and 3.
J Med Chem 49: 172-8 (2006)
The Danish University of Pharmaceutical Sciences
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
J Med Chem 49: 159-71 (2006)
National Institute of Allergy and Infectious Diseases
Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization.
J Med Chem 49: 135-58 (2006)
Wyeth Research
Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.
J Med Chem 49: 125-34 (2006)
Columbia University College of Physicians and Surgeons
Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model.
J Med Chem 49: 80-91 (2006)
Toyama Chemical
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
J Med Chem 49: 70-9 (2006)
University of Lille
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
J Med Chem 49: 51-69 (2006)
Aventis Pharma Deutschland
Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents.
J Med Chem 49: 39-42 (2006)
Achillion Pharmaceuticals
Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
J Med Chem 49: 35-8 (2006)
Merck Sharp Laboratory
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies.
J Med Chem 49: 27-30 (2006)
Burnham Institute
6H,13H-Pyrazino[1,2-a;4,5-a']diindole analogs: probing the pharmacophore for allosteric ligands of muscarinic M2 receptors.
Bioorg Med Chem Lett 16: 1481-5 (2006)
University of W£Rzburg
Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
Bioorg Med Chem Lett 16: 1621-7 (2006)
Schering-Plough Research Institute
Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.
Bioorg Med Chem Lett 16: 1616-20 (2006)
National Hellenic Research Foundation
1,2,3,4-Tetrahydroisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors.
Bioorg Med Chem Lett 16: 1574-8 (2006)
Procter & Gamble Pharmaceuticals
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Bioorg Med Chem Lett 16: 1532-6 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
8-Fluoroimidazo[1,2-a]pyridine: synthesis, physicochemical properties and evaluation as a bioisosteric replacement for imidazo[1,2-a]pyrimidine in an allosteric modulator ligand of the GABA A receptor.
Bioorg Med Chem Lett 16: 1518-22 (2006)
Merck Sharp and Dohme Research Laboratories
Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Bioorg Med Chem Lett 16: 1477-80 (2006)
Merck Sharp and Dohme Research Laboratories
Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.
Bioorg Med Chem Lett 16: 1527-31 (2006)
Hawaii Biotech
Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands.
Bioorg Med Chem Lett 16: 1549-52 (2006)
Boehringer Ingelheim Pharmaceuticals
Synthesis and insecticidal activity of fluorinated 2-(2,6-dichloro-4-trifluoromethylphenyl)-2,4,5,6-tetrahydrocyclopentapyrazoles.
Bioorg Med Chem Lett 16: 1702-6 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
Bioorg Med Chem Lett 16: 1579-81 (2006)
Imclone Systems
Discovery and optimization of a novel series of liver X receptor-alpha agonists.
Bioorg Med Chem Lett 16: 1638-42 (2006)
Amgen
Imidazo[1,2-a]pyrazin-8-ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8-ones as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Bioorg Med Chem Lett 16: 1582-5 (2006)
Merck Sharp and Dohme Research Laboratories
Design and synthesis of potent and subtype-selective PPARalpha agonists.
Bioorg Med Chem Lett 16: 1673-8 (2006)
Merck Research Laboratories
CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.
Bioorg Med Chem Lett 16: 1716-20 (2006)
Genentech
Novel lactam NK1 antagonists with anti-emetic activity.
Bioorg Med Chem Lett 16: 1197-201 (2006)
Merck Sharp & Dohme Research Laboratories
Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3).
Chem Biol Interact 159: 169-79 (2006)
Laboratoire De Pharmacologie-Toxicologie Inra
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
Bioorg Med Chem Lett 16: 1633-7 (2006)
Astrazeneca
Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity.
Bioorg Med Chem Lett 16: 1586-9 (2006)
Institut Henri Beaufour
Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels.
Bioorg Med Chem Lett 16: 1138-41 (2006)
Abbott Laboratories
Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
Bioorg Med Chem Lett 16: 1696-701 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues.
Bioorg Med Chem Lett 16: 1142-5 (2006)
Astrazeneca R&D
Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.
Bioorg Med Chem Lett 16: 1134-7 (2006)
Nantes University
5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethers.
Bioorg Med Chem Lett 16: 1202-6 (2006)
Pfizer
Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Bioorg Med Chem Lett 16: 1544-8 (2006)
Schering-Plough Research Institute
4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors.
Bioorg Med Chem Lett 16: 1502-5 (2006)
Sankyo
Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.
J Nat Prod 68: 1793-5 (2005)
University of ZüRich
Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists.
Bioorg Med Chem 14: 2725-46 (2006)
Daiichi Pharmaceutical
Novel endotoxin-sequestering compounds with terephthalaldehyde-bis-guanylhydrazone scaffolds.
Bioorg Med Chem Lett 16: 1305-8 (2006)
University of Kansas
The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors.
Bioorg Med Chem Lett 16: 1744-8 (2006)
Santhera Pharmaceuticals
Asymmetric synthesis of the L-fuco-nojirimycin, a nanomolar alpha-L-fucosidase inhibitor.
Bioorg Med Chem Lett 16: 1172-4 (2006)
Université
New benzimidazoles as thrombopoietin receptor agonists.
Bioorg Med Chem Lett 16: 1212-6 (2006)
Glaxosmithkline
Seco-prolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1.
Bioorg Med Chem Lett 16: 1731-4 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists.
Bioorg Med Chem Lett 16: 1721-5 (2006)
Procter & Gamble Pharmaceuticals
Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Bioorg Med Chem Lett 16: 1735-9 (2006)
Glaxosmithkline
Actin is the primary cellular receptor of bistramide A.
Nat Chem Biol 1: 383-8 (2005)
University of Chicago
C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L.
Nat Chem Biol 1: 377-82 (2005)
Institut De Biologie MoléCulaire Et Cellulaire
Monocarboxylate transporter MCT1 is a target for immunosuppression.
Nat Chem Biol 1: 371-6 (2005)
Astrazeneca R&D Charnwood
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Bioorg Med Chem Lett 16: 1146-50 (2006)
Merck Research Laboratories
Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
J Med Chem 48: 8289-98 (2005)
Johnson & Johnson Pharmaceutical Research and Development
Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition.
J Med Chem 48: 8270-88 (2005)
University of Bonn
2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching.
J Med Chem 48: 8253-60 (2005)
University of Naples Federico II
Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor.
J Med Chem 48: 8237-44 (2005)
University of Bari Aldo Moro
Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).
J Med Chem 48: 8229-36 (2005)
Progen Industries
Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
J Med Chem 48: 8194-208 (2005)
National Health Research Institutes
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
J Med Chem 48: 8163-73 (2005)
Johnson & Johnson Pharmaceutical Research and Development
Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
J Med Chem 48: 8148-54 (2005)
University of Pavia
Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase.
J Med Chem 48: 8134-47 (2005)
Chuq-Pavillon Chul and Université
Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).
J Med Chem 48: 8112-4 (2005)
University of Cagliari
Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference.
J Med Chem 48: 8108-11 (2005)
Niddk
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.
J Med Chem 48: 8103-7 (2005)
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists.
Bioorg Med Chem Lett 16: 1749-52 (2006)
Glaxosmithkline
2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Bioorg Med Chem Lett 16: 1726-30 (2006)
Chemical Diversity
Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.
Bioorg Med Chem Lett 16: 1130-3 (2006)
Merck Research Laboratories
Aza-retinoids as novel retinoid X receptor-specific agonists.
Bioorg Med Chem Lett 16: 2352-6 (2006)
Ligand Pharmaceuticals
Probing structure/affinity relationships for the Plasmodium falciparum hexose transporter with glucose derivatives.
Bioorg Med Chem Lett 16: 1267-71 (2006)
Université
Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.
Bioorg Med Chem Lett 16: 1207-11 (2006)
F. Hoffmann-La Roche
Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Bioorg Med Chem Lett 16: 1151-5 (2006)
Cephalon
A topological function based on spectral moments for predicting affinity toward A3 adenosine receptors.
Bioorg Med Chem Lett 16: 1291-6 (2006)
Vigo University
Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors.
Bioorg Med Chem Lett 16: 1753-6 (2006)
University of Alexandria
Protein tyrosine phosphatase 1B inhibitors from Morus root bark.
Bioorg Med Chem Lett 16: 1426-9 (2006)
Korea Research Institute of Bioscience and Biotechnology (Kribb)
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
Proc Natl Acad Sci U S A 102: 18620-5 (2005)
Mcgill University
Triaminotriazine DNA helicase inhibitors with antibacterial activity.
Bioorg Med Chem Lett 16: 1286-90 (2006)
Targanta Therapeutics
Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
J Pharmacol Exp Ther 317: 147-52 (2006)
University of Tours
Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta.
Bioorg Med Chem Lett 16: 1240-4 (2006)
Karo Bio
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Bioorg Med Chem Lett 16: 964-8 (2006)
Merck Research Laboratories
Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.
Bioorg Med Chem Lett 16: 1297-300 (2006)
University of Tours
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Bioorg Med Chem Lett 16: 1272-6 (2006)
Achillion Pharmaceuticals
Aminoalkyl phenyl sulfones--a novel series of 5-HT7 receptor ligands.
Bioorg Med Chem Lett 16: 1255-8 (2006)
Merck Sharp and Dohme Research Laboratories
Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
Bioorg Med Chem Lett 16: 1277-81 (2006)
Achillion Pharmaceuticals
Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.
Bioorg Med Chem Lett 16: 1371-9 (2006)
Sumitomo Pharmaceuticals
High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
J Mol Biol 356: 45-56 (2006)
Philipps University Marburg
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
Bioorg Med Chem Lett 16: 1320-23 (2006)
Astrazeneca
Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers.
Bioorg Med Chem Lett 16: 1358-61 (2006)
Merck Research Laboratories
Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
Bioorg Med Chem Lett 16: 1397-401 (2006)
Astrazeneca R&D SöDertäLje
Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase.
Bioorg Med Chem Lett 16: 1335-7 (2006)
Academy of Sciences of The Czech Republic
From pyrroles to pyrrolo[1,2-a]pyrazinones: a new class of mGluR1 antagonists.
Bioorg Med Chem Lett 16: 1342-5 (2006)
Glaxosmithkline
A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
J Med Chem 48: 8098-102 (2005)
Uppsala University
Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide.
J Med Chem 48: 8087-97 (2005)
University of Manchester
cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach.
J Med Chem 48: 8079-86 (2005)
University of Hamburg
Synthesis and biological evaluation of a novel series of"ortho-nitrated" inhibitors of catechol-O-methyltransferase.
J Med Chem 48: 8070-8 (2005)
Department of Research & Development
Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.
J Med Chem 48: 8045-54 (2005)
Elixir Pharmaceuticals
Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
J Med Chem 48: 8035-44 (2005)
Kobe Gakuin University
Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
J Med Chem 48: 8009-15 (2005)
University of Southern California
Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.
J Med Chem 48: 7980-92 (2005)
Université
Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors.
J Med Chem 48: 7970-9 (2005)
University of Illinois At Chicago
Use of structure-based drug design approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors.
J Med Chem 48: 7960-9 (2005)
Wyeth Research
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
J Med Chem 48: 7932-45 (2005)
Università
First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure.
J Med Chem 48: 7919-22 (2005)
Università
Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
Bioorg Med Chem Lett 16: 1338-41 (2006)
Wyeth Research
Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
Bioorg Med Chem Lett 16: 1346-9 (2006)
Merck Research Laboratories
Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
Bioorg Med Chem Lett 16: 1362-5 (2006)
F. Hoffmann-La Roche
Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging.
Bioorg Med Chem Lett 16: 1350-2 (2006)
University of Pennsylvania
Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Bioorg Med Chem Lett 16: 1353-7 (2006)
Vernalis (R&D)
Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
Bioorg Med Chem Lett 16: 1440-4 (2006)
Chemical Diversity
Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.
Bioorg Med Chem Lett 16: 737-42 (2005)
Korea Research Institute of Chemical Technology
Expedited SAR study of high-affinity ligands to the alpha(2)delta subunit of voltage-gated calcium channels: Generation of a focused library using a solution-phase Sn2Ar coupling methodology.
Bioorg Med Chem Lett 16: 746-9 (2005)
Merck Research Laboratories
Synthesis and biological characterization of [3H] (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer.
Bioorg Med Chem Lett 16: 1402-4 (2006)
Università
In silico fragment-based discovery of DPP-IV S1 pocket binders.
Bioorg Med Chem Lett 16: 1405-9 (2006)
Santhera Pharmaceuticals
Sarcosine based indandione hGlyT1 inhibitors.
Bioorg Med Chem Lett 16: 1388-91 (2006)
Merck Sharp and Dohme Research Laboratories
Strong solute-solute dispersive interactions in a protein-ligand complex.
J Am Chem Soc 127: 17061-7 (2005)
University of Leeds
Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.
Bioorg Med Chem Lett 16: 1434-9 (2006)
Pfizer
Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.
Bioorg Med Chem Lett 16: 798-802 (2006)
Ajinomoto
Androstenediol analogs as ER-beta-selective SERMs.
Bioorg Med Chem Lett 16: 834-8 (2006)
Merck Research Laboratories
Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties.
Bioorg Med Chem Lett 16: 825-9 (2006)
Aristotelian University of Thessaloniki
(+)-Myristinins A and D from Knema elegans, which inhibit DNA polymerase beta and cleave DNA.
J Nat Prod 68: 1625-8 (2005)
University of Virginia
Free-radical-scavenging and xanthine oxidase inhibitory constituents from Stereospermum personatum.
J Nat Prod 68: 1615-21 (2005)
Institute of Chemical Technology
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
Bioorg Med Chem Lett 16: 821-4 (2006)
Gsk
Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.
Bioorg Med Chem Lett 16: 811-4 (2006)
Merck Sharp & Dohme Research Laboratories
Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.
Bioorg Med Chem 14: 2162-77 (2006)
Wyeth Research
Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta.
Bioorg Med Chem Lett 16: 884-6 (2006)
Karo Bio
Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Bioorg Med Chem Lett 16: 845-9 (2006)
Pfizer
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
J Med Chem 48: 7882-905 (2005)
Serono Pharmaceutical Research Institute
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
J Med Chem 48: 7867-81 (2005)
University Walk
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
J Med Chem 48: 7860-6 (2005)
Kochi Medical School
On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies.
J Med Chem 48: 7847-59 (2005)
Umr Cnrs/Ulp 7081
Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
J Med Chem 48: 7829-46 (2005)
School of Natural Sciences--Chemistry
Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds.
J Med Chem 48: 7808-20 (2005)
Metabasis Therapeutics
Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors.
J Med Chem 48: 7789-95 (2005)
Sapienza University of Rome
Small molecule inhibitors of dynamin I GTPase activity: development of dimeric tyrphostins.
J Med Chem 48: 7781-8 (2005)
The University of Newcastle
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate
J Med Chem 48: 7750-63 (2005)
University of Camerino
Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents.
J Med Chem 48: 7720-32 (2005)
Technische UniversitäT MüNchen
Mono- or diphenylpyridazines connected to N-(2,4-difluorophenyl)-N'-heptylurea as acyl-CoA:cholesterol acyltransferase inhibitors.
J Med Chem 48: 7708-13 (2005)
Università
Interaction of papain-like cysteine proteases with dipeptide-derived nitriles.
J Med Chem 48: 7688-707 (2005)
Rheinische Friedrich-Wilhelms-Universitat Bonn
Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders.
J Med Chem 48: 7675-87 (2005)
University of Parma
Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics.
J Med Chem 48: 7667-74 (2005)
Instituto De QuíMica MéDica (Csic)
N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies.
J Med Chem 48: 7637-47 (2005)
Washington University
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
J Med Chem 48: 7604-14 (2005)
Oxford University
3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.
J Med Chem 48: 7592-603 (2005)
University of Namur
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
J Med Chem 48: 7560-81 (2005)
Wyeth Research
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
J Med Chem 48: 7535-43 (2005)
Merck Frosst Centre For Therapeutic Research
Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.
J Med Chem 48: 7520-34 (2005)
Celera Genomics
Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
J Med Chem 48: 7517-9 (2005)
Acadia Pharmaceuticals
Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter.
J Med Chem 48: 7513-6 (2005)
National Institute On Drug Abuse-Intramural Research Program
Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands.
Bioorg Med Chem Lett 16: 854-8 (2006)
Wyeth Research
Aplysamine-1 and related analogs as histamine H3 receptor antagonists.
Bioorg Med Chem Lett 16: 897-900 (2006)
Johnson & Johnson Pharmaceutical Research and Development
Inhibition of DNA helicases with DNA-competitive inhibitors.
Bioorg Med Chem Lett 16: 923-7 (2006)
Novartis Institutes For Biomedical Research
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
Bioorg Med Chem Lett 16: 859-63 (2006)
University of Pennsylvania
Synthesis and structure-activity relationships of a new series of 2alpha-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as mu-selective opioid antagonists.
Bioorg Med Chem Lett 16: 864-8 (2006)
Adolor
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5.
Bioorg Med Chem Lett 16: 2347-51 (2006)
Eli Lilly
Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC.
Bioorg Med Chem Lett 16: 891-6 (2006)
Targanta Therapeutics
Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.
Bioorg Med Chem Lett 16: 984-8 (2006)
Schering-Plough Research Institute
Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Bioorg Med Chem Lett 16: 839-44 (2006)
Pfizer
Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
Bioorg Med Chem Lett 16: 960-3 (2006)
Astrazeneca R&D Charnwood
Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Bioorg Med Chem Lett 16: 954-9 (2006)
Wyeth Research
Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
Bioorg Med Chem Lett 16: 934-7 (2006)
Pharmaceutical Research Institute
Synthesis and structure-activity relationships of novel dipeptides and reduced dipeptides as ligands for melanocortin subtype-4 receptor.
Bioorg Med Chem Lett 16: 2341-6 (2006)
Eli Lilly
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
Bioorg Med Chem Lett 16: 989-94 (2006)
The Schering Plough Research Institute
Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?
Bioorg Med Chem Lett 16: 978-83 (2006)
Glaxosmithkline
Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.
Bioorg Med Chem Lett 16: 938-42 (2006)
Cephalon
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
Bioorg Med Chem Lett 16: 905-10 (2006)
Pfizer
Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
Bioorg Med Chem Lett 16: 1040-4 (2006)
Kudos Pharmaceuticals
Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
Bioorg Med Chem Lett 16: 1032-6 (2006)
University of Montreal
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
Bioorg Med Chem Lett 16: 1084-90 (2006)
Nerviano Medical Sciences
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II"selective" inhibitor celecoxib.
Bioorg Med Chem Lett 16: 437-42 (2005)
Istituto Di Biostrutture E Bioimmagini-Cnr
Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives.
Bioorg Med Chem Lett 16: 592-5 (2005)
Huazhong University of Science and Technology
Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.
Bioorg Med Chem Lett 16: 1080-3 (2006)
Universidad De Santiago De Compostela
Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
Bioorg Med Chem Lett 16: 1065-9 (2006)
Schering-Plough Research Institute
Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.
Bioorg Med Chem Lett 16: 443-6 (2005)
University of Michigan
Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives.
Bioorg Med Chem Lett 16: 490-4 (2005)
Abbott
Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.
Bioorg Med Chem Lett 16: 451-6 (2005)
University of Tennessee Health Science Center
Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.
Bioorg Med Chem 14: 1792-804 (2006)
Vernalis (R&D)
PTP-1B inhibitors: cyclopenta[d][1,2]-oxazine derivatives.
Bioorg Med Chem Lett 16: 499-502 (2005)
Korea Research Institute of Chemical Technology
Conversion of potent MMP inhibitors into selective TACE inhibitors.
Bioorg Med Chem Lett 16: 1028-31 (2006)
Bristol-Myers Squibb Pharmaceutical Research Institute
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.
Bioorg Med Chem Lett 16: 596-601 (2005)
National Institute of Diabetes and Digestive and Kidney Diseases
6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: structure-activity exploration of eastern and western parts.
Bioorg Med Chem Lett 16: 1070-5 (2006)
7Tm Pharma
Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc.
Bioorg Med Chem Lett 16: 507-11 (2005)
Pharmacopeia
A novel nicotinic acetylcholine receptor antagonist radioligand for PET studies.
Bioorg Med Chem Lett 16: 1049-53 (2006)
Brookhaven National Laboratory
Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors.
Bioorg Med Chem Lett 16: 1005-9 (2006)
Jagiellonian University
The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.
Bioorg Med Chem Lett 16: 1060-4 (2006)
Pfizer
Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.
Bioorg Med Chem 14: 1378-90 (2006)
Fujisawa Pharmaceutical
In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors.
Bioorg Med Chem Lett 16: 525-8 (2005)
Cytrx Laboratories
Random chemistry as a new tool for the generation of small compound libraries: development of a new acetylcholinesterase inhibitor.
J Med Chem 48: 7496-9 (2005)
University of WüRzburg
Synthesis and pharmacological characterization of exo-2-(2'-chloro-5-pyridinyl)-7-(endo and exo)-aminobicyclo[2.2.1]heptanes as novel epibatidine analogues.
J Med Chem 48: 7491-5 (2005)
Research Triangle Institute
1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
J Med Chem 48: 7486-90 (2005)
University of Louvain
Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
J Med Chem 48: 7445-56 (2005)
Lawrence Berkeley National Laboratory
Synthesis and monoamine transporter binding properties of 2,3-diaryltropanes.
J Med Chem 48: 7437-44 (2005)
Research Triangle Institute
Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.
J Med Chem 48: 7400-10 (2005)
Biochemie-Zentrum Der UniversitäT Heidelberg
Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.
J Med Chem 48: 7374-88 (2005)
Abbott Laboratories
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
J Med Chem 48: 7351-62 (2005)
Università
Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
J Med Chem 48: 7343-50 (2005)
University of Siena
Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
J Med Chem 48: 7333-42 (2005)
University College London
Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach.
J Med Chem 48: 7282-9 (2005)
University of Bologna
Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain.
J Med Chem 48: 7253-60 (2005)
Nagasaki University
Structural, mutagenic, and kinetic analysis of the binding of substrates and inhibitors of human phenylethanolamine N-methyltransferase.
J Med Chem 48: 7243-52 (2005)
University of Michigan
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
J Med Chem 48: 7223-33 (2005)
Neuropharma
Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and a
J Med Chem 48: 7215-22 (2005)
Duquesne University
Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors.
J Med Chem 48: 7172-85 (2005)
Università
Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
J Med Chem 48: 7166-71 (2005)
University of Kuopio
Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives.
J Med Chem 48: 7113-22 (2005)
Sapienza University of Rome
SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
J Med Chem 48: 7103-12 (2005)
Instituto De Quimica Medica (Csic)
Synthesis and characterization of the novel fluorescent prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(hydroxyacetyl)pyrrolidine.
J Med Chem 48: 7093-5 (2005)
University of Kuopio
7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
J Med Chem 48: 7089-92 (2005)
Merck Sharp and Dohme Research Laboratories
Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.
J Mol Biol 354: 789-800 (2005)
Georgia State University
Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
Bioorg Med Chem Lett 16: 302-6 (2005)
Cv Therapeutics
Potent anti-muscarinic activity in a novel series of quinuclidine derivatives.
Bioorg Med Chem Lett 16: 373-7 (2005)
Ucb Pharma
Synthesis and biological activity of the first cyclic biphalin analogues.
Bioorg Med Chem Lett 16: 367-72 (2005)
University of Arizona
Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.
Bioorg Med Chem Lett 16: 311-6 (2006)
Wyeth Research
New tyrosinase inhibitors selected by atomic linear indices-based classification models.
Bioorg Med Chem Lett 16: 324-30 (2005)
Central University of Las Villas
Substituted indanylacetic acids as PPAR-alpha-gamma activators.
Bioorg Med Chem Lett 16: 297-301 (2005)
Bayer Research Center
4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.
Bioorg Med Chem Lett 16: 280-4 (2006)
Merck Research Laboratories
Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
Bioorg Med Chem Lett 16: 554-8 (2005)
University of Tokyo
Pyrrolopyridazine MEK inhibitors.
Bioorg Med Chem Lett 16: 628-32 (2005)
Pharmaceutical Research Institute
5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog.
Bioorg Med Chem Lett 16: 288-92 (2005)
Veterinary Medicine Research and Development Pfizer
Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids.
Bioorg Med Chem Lett 16: 257-61 (2005)
Universidad De Santiago De Compostela
N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
Bioorg Med Chem Lett 16: 602-6 (2006)
Chemical Diversity
A new chemical tool for exploring the physiological function of the PDE2 isozyme.
Bioorg Med Chem Lett 16: 307-10 (2005)
Pfizer
Tethering identifies fragment that yields potent inhibitors of human caspase-1.
Bioorg Med Chem Lett 16: 559-62 (2005)
Sunesis Pharmaceuticals
Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.
Bioorg Med Chem Lett 16: 457-60 (2005)
Wyeth Research
Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum.
Bioorg Med Chem Lett 16: 573-80 (2005)
University of Karachi
Design, synthesis and structure-activity relationships of new phosphinate inhibitors of MurD.
Bioorg Med Chem Lett 16: 343-8 (2005)
University of Ljubljana
Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.
Bioorg Med Chem Lett 16: 658-62 (2005)
Abbott
Side-chain modified analogues of histaprodifen: asymmetric synthesis and histamine H1-receptor activity.
Bioorg Med Chem Lett 16: 672-6 (2006)
Universit£T Regensburg
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists.
Bioorg Med Chem Lett 16: 681-5 (2005)
Merck Research Laboratories
New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.
Bioorg Med Chem Lett 16: 731-6 (2005)
Pfizer
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
Bioorg Med Chem Lett 16: 633-40 (2005)
University of Tennessee Health Science Center
Conformationally biased P3 amide replacements of beta-secretase inhibitors.
Bioorg Med Chem Lett 16: 641-4 (2006)
Merck Research Laboratories
Design, synthesis and in vitro antimalarial activity of an acylhydrazone library.
Bioorg Med Chem Lett 16: 31-5 (2005)
University of Lille
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
Bioorg Med Chem Lett 16: 718-21 (2005)
Pfizer
Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists.
Bioorg Med Chem Lett 16: 645-8 (2005)
Adolor
A concise asymmetric route for the synthesis of a novel class of glucocorticoid mimetics containing a trifluoromethyl-substituted alcohol.
Bioorg Med Chem Lett 16: 654-7 (2005)
Boehringer Ingelheim Pharmaceuticals
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.
Bioorg Med Chem Lett 16: 378-81 (2005)
Glaxosmithkline
Synthesis of N-benzylated-2-aminoquinolines as ligands for the Tec SH3 domain.
Bioorg Med Chem Lett 16: 387-90 (2005)
The University of Adelaide
Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase.
Bioorg Med Chem Lett 16: 100-3 (2005)
Viropharma
Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.
Bioorg Med Chem Lett 16: 677-80 (2005)
Vernalis
Derivatives of tramadol for increased duration of effect.
Bioorg Med Chem Lett 16: 691-4 (2005)
Sepracor
Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.
Bioorg Med Chem Lett 16: 710-3 (2005)
Celera
Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 1: Weakly basic azoles.
Bioorg Med Chem Lett 16: 338-42 (2005)
Merck Research Laboratories
Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors.
Bioorg Med Chem Lett 16: 695-700 (2005)
Chugai Pharma Usa
Anti-inflammatory acylphloroglucinol derivatives from Hops (Humulus lupulus).
J Nat Prod 68: 1545-8 (2005)
Fr. 8.2 Pharmakognosie Und Analytische Phytochemie Der UniversitäT Des Saarlandes
Phenolic and triterpene glycosides from the stems of Ilex litseaefolia.
J Nat Prod 68: 1531-5 (2005)
Chinese Academy of Sciences
Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum.
J Nat Prod 68: 1514-8 (2005)
Chinese Academy of Sciences
Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
J Med Chem 48: 7084-8 (2005)
Università
Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils.
J Med Chem 48: 7063-74 (2005)
Glsynthesis
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
J Med Chem 48: 7040-8 (2005)
University of Bonn
Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors.
J Med Chem 48: 7024-39 (2005)
Umr 8525 Cnrs-Université
11C-labeling of n-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide derivatives and evaluation as potential radioligands for PET imaging of dopamine D3 receptors.
J Med Chem 48: 7018-23 (2005)
University of Milano/Bicocca
Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.
J Med Chem 48: 6997-7004 (2005)
Johann Wolfgang Goethe-UniversitäT
Fast small molecule similarity searching with multiple alignment profiles of molecules represented in one-dimension.
J Med Chem 48: 6980-90 (2005)
Pharmacopeia
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
J Med Chem 48: 6956-69 (2005)
Glaxosmithkline
Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.
J Med Chem 48: 6948-55 (2005)
University of Perugia
Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.
J Med Chem 48: 6908-17 (2005)
Brown University
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
J Med Chem 48: 6887-96 (2005)
University of Urbino
Azepanone-based inhibitors of human cathepsin L.
J Med Chem 48: 6870-8 (2005)
Glaxosmithkline
Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
J Med Chem 48: 6855-69 (2005)
Solvay Pharma
Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
J Med Chem 48: 6843-54 (2005)
Universidad San Pablo Ceu
Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists.
J Med Chem 48: 6813-20 (2005)
M.V. Lomonosov Moscow State University
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
J Med Chem 48: 6803-12 (2005)
James Black Foundation
Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
J Med Chem 48: 6790-802 (2005)
James Black Foundation
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
J Med Chem 48: 6772-5 (2005)
Eli Lilly
Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.
J Med Chem 48: 6767-71 (2005)
Purdue University
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.
Proc Natl Acad Sci U S A 102: 16078-83 (2005)
Glaxosmithkline
The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
J Biol Chem 281: 260-8 (2006)
Vertex Pharmaceuticals
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
Bioorg Med Chem 14: 1255-73 (2006)
Uk Centre For Cancer Therapeutics
Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.
Bioorg Med Chem Lett 16: 262-6 (2005)
Novartis Institutes For Biomedical Research
Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex.
Bioorg Med Chem Lett 16: 191-5 (2006)
Eli Lilly
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Curr Drug Metab 6: 413-54 (2005)
F. Hoffmann-La Roche
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.
Bioorg Med Chem Lett 16: 40-3 (2005)
Novartis Institute For Tropical Diseases
Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
Bioorg Med Chem Lett 16: 25-30 (2006)
Saarland University
Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile.
Bioorg Med Chem Lett 16: 354-7 (2005)
F. Hoffmann-La Roche
1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.
Bioorg Med Chem Lett 16: 409-12 (2005)
Imclone Systems
Biphenyl-4-ylcarbamoyl thiophene carboxylic acids as potent DHODH inhibitors.
Bioorg Med Chem Lett 16: 267-70 (2006)
4Sc
Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors.
Bioorg Med Chem Lett 16: 349-53 (2005)
F. Hoffmann-La Roche
Pentacyclic triterpenes. Part 2: Synthesis and biological evaluation of maslinic acid derivatives as glycogen phosphorylase inhibitors.
Bioorg Med Chem Lett 16: 722-6 (2005)
China Pharmaceutical University
Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp.
Bioorg Med Chem Lett 16: 69-71 (2006)
Kanazawa University
Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.
Bioorg Med Chem Lett 16: 36-9 (2005)
Novartis Institute For Tropical Diseases
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
Bioorg Med Chem Lett 16: 395-9 (2005)
The Schering Plough Research Institute
N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors.
Bioorg Med Chem Lett 16: 404-8 (2005)
Imclone Systems
Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I).
Bioorg Med Chem Lett 16: 225-7 (2005)
Fudan University
M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.
J Pharmacol Exp Ther 316: 869-74 (2006)
Temple University
A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.
Chem Biol 12: 1103-15 (2005)
Gpc Biotech
Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors.
Bioorg Med Chem 14: 1215-20 (2006)
Lund University
N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.
Bioorg Med Chem Lett 16: 20-4 (2005)
Università
Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors.
Bioorg Med Chem Lett 16: 421-6 (2006)
Abbott Laboratories
Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative.
Bioorg Med Chem Lett 16: 55-8 (2005)
Fujisawa Pharmaceutical
Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor with improved aqueous solubility.
Bioorg Med Chem Lett 16: 44-8 (2005)
Sumitomo Pharmaceuticals
p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones.
Bioorg Med Chem Lett 16: 64-8 (2005)
Merck
Diastereomeric molecular recognition and binding behavior of bile acids by L/D-tryptophan-modified beta-cyclodextrins.
J Org Chem 70: 8703-11 (2005)
Nankai University
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists.
Bioorg Med Chem Lett 16: 146-9 (2005)
Johnson and Johnson Pharmaceutical Research and Development
N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase.
Bioorg Med Chem Lett 15: 5375-7 (2005)
Université
3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors.
Bioorg Med Chem Lett 16: 59-63 (2005)
Technische UniversitäT MüNchen
NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.
Bioorg Med Chem Lett 16: 84-7 (2006)
Novartis Institutes For Biomedical Research
Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
Bioorg Med Chem Lett 16: 108-12 (2005)
Novartis Institutes For Biomedical Research
Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
Bioorg Med Chem Lett 16: 123-8 (2006)
Johnson & Johnson Pharmaceutical
Optimization of CCR4 antagonists: side-chain exploration.
Bioorg Med Chem Lett 16: 204-7 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.
Bioorg Med Chem Lett 15: 5494-8 (2005)
Eisai Research Institute
Synthesis and monoamine transporter affinity of new 2beta-carbomethoxy-3beta-[aryl or heteroaryl]phenyltropanes.
Bioorg Med Chem Lett 16: 217-20 (2005)
Yale University
The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Bioorg Med Chem Lett 16: 88-92 (2006)
University of Leeds
Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE.
Bioorg Med Chem 13: 6588-97 (2005)
Neuropharma
Molecular docking and 3D-QSAR on 2-(oxalylamino) benzoic acid and its analogues as protein tyrosine phosphatase 1B inhibitors.
Bioorg Med Chem Lett 15: 5521-5 (2005)
Graduate University of Chinese Academy of Sciences
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
J Med Chem 48: 6713-30 (2005)
Pfizer
Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
J Med Chem 48: 6661-70 (2005)
The University of Texas At Houston
Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position.
J Med Chem 48: 6653-60 (2005)
Instituto De QuíMica MéDica (Csic)
Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells.
J Med Chem 48: 6643-52 (2005)
University of California San Diego
Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
J Med Chem 48: 6632-42 (2005)
Saarland University
Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity.
J Med Chem 48: 6620-31 (2005)
Uppsala University
Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.
J Med Chem 48: 6607-19 (2005)
Philipps-Universitat Marburg
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
J Med Chem 48: 6597-606 (2005)
Astellas Pharma
Receptor flexibility in de novo ligand design and docking.
J Med Chem 48: 6585-96 (2005)
De Novo Pharmaceuticals
Selective inhibition of MCF-7(piGST) breast tumors using glutathione transferase-derived 2-methylene-cycloalkenones.
J Med Chem 48: 6549-52 (2005)
University of Maryland
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.
J Med Chem 48: 6544-8 (2005)
Incyte
Designed multiple ligands. An emerging drug discovery paradigm.
J Med Chem 48: 6523-43 (2005)
Organon Laboratories
Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.
Bioorg Med Chem Lett 15: 5567-73 (2005)
Abbott
Metalloform-selective inhibition: synthesis and structure-activity analysis of Mn(II)-form-selective inhibitors of Escherichia coli methionine aminopeptidase.
Bioorg Med Chem Lett 15: 5386-91 (2005)
Graduate School of Chinese Academy of Sciences
Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Bioorg Med Chem Lett 15: 5562-6 (2005)
Pfizer
Novel inhibitors of the mitochondrial respiratory chain: oximes and pyrrolines isolated from Penicillium brevicompactum and synthetic analogues.
J Agric Food Chem 53: 8296-301 (2005)
Universidad Polit£Cnica De Valencia
Novel triazole based inhibitors of Ras farnesyl transferase.
Bioorg Med Chem Lett 15: 5407-11 (2005)
Janssen Research Foundation
Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists.
Bioorg Med Chem Lett 15: 5478-82 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1beta converting enzyme inhibitors.
Bioorg Med Chem Lett 15: 5434-8 (2005)
Procter & Gamble Pharmaceuticals
3-Arylpiperazinylethyl-1H-pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione derivatives as novel, high-affinity and selective alpha(1)-adrenoceptor ligands.
Bioorg Med Chem Lett 16: 150-3 (2005)
Università
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
Bioorg Med Chem Lett 16: 113-7 (2005)
Novartis Institutes For Biomedical Research
Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases.
Bioorg Med Chem Lett 16: 129-33 (2005)
Korea Research Institute of Chemical Technology
Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors.
Bioorg Med Chem Lett 16: 96-9 (2005)
Abbott Laboratories
New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists.
Bioorg Med Chem Lett 16: 167-70 (2005)
Università
Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C.
Bioorg Med Chem Lett 16: 171-5 (2005)
Institut Henri Beaufour
Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.
Bioorg Med Chem Lett 15: 5365-9 (2005)
University of WüRzburg
Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
Bioorg Med Chem Lett 16: 118-22 (2005)
Abbott Bioresearch Center
Pulvinones as bacterial cell wall biosynthesis inhibitors.
Bioorg Med Chem Lett 16: 176-80 (2006)
Wyeth Research
Synthesis and biological evaluation of novel EG5 inhibitors.
Chembiochem 6: 2005-13 (2005)
University of Leipzig
Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors.
Bioorg Med Chem Lett 15: 5450-2 (2005)
University of Bonn
Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists.
Bioorg Med Chem Lett 16: 200-3 (2005)
Pharmacopeia Drug Discovery
N-8-Substituted benztropinamine analogs as selective dopamine transporter ligands.
Bioorg Med Chem Lett 15: 5419-23 (2005)
National Institute On Drug Abuse-Intramural Research Program
Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
Bioorg Med Chem Lett 15: 5382-5 (2005)
The Ohio State University
New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
Bioorg Med Chem Lett 16: 138-41 (2005)
Institute of Biomolecular Chemistry
3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone.
Bioorg Med Chem Lett 15: 5197-201 (2005)
Vernalis (R&D)
Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives.
Bioorg Med Chem Lett 15: 5129-35 (2005)
Universidade Do Porto
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.
Bioorg Med Chem Lett 15: 5453-8 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and preliminary biological evaluation of (2S,1'R,2'S)- and (2S,1'S,2'R)-2-(2'-phosphonocyclopropyl)glycines, two novel conformationally constrained l-AP4 analogues.
Bioorg Med Chem Lett 16: 196-9 (2005)
University of Perugia
Geometric diversity through permutation of backbone configuration in cyclic peptide libraries.
Bioorg Med Chem Lett 15: 5329-34 (2005)
Harvard Medical School
Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II.
Bioorg Med Chem Lett 15: 5429-33 (2005)
Griffith University
Inhibitors designed for the active site of dihydroorotase.
Bioorg Chem 33: 470-83 (2005)
Texas A&M University
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.
Bioorg Med Chem Lett 15: 5344-52 (2005)
F. Hoffmann-La Roche
Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.
J Enzyme Inhib Med Chem 20: 401-7 (2005)
University of Karachi
6-(N-benzoylamino)purine as a novel and potent inhibitor of xanthine oxidase: inhibition mechanism and molecular modeling studies.
J Enzyme Inhib Med Chem 20: 317-24 (2005)
National Institute of Pharmaceutical Education and Research
The structure of Cryptococcus neoformans thymidylate synthase suggests strategies for using target dynamics for species-specific inhibition.
Acta Crystallogr D Biol Crystallogr 61: 1320-34 (2005)
University of California San Francisco
Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
J Pharmacol Exp Ther 316: 654-61 (2006)
Medical College of Georgia
Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
Bioorg Med Chem Lett 15: 5311-4 (2005)
Merck Research Laboratories
Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides.
Bioorg Med Chem Lett 15: 5192-6 (2005)
Universita Degli Studi Di Firenze
Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
Bioorg Med Chem Lett 15: 5499-503 (2005)
Abbott Laboratories
Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints.
Bioorg Med Chem Lett 15: 5114-9 (2005)
Adolor
New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors.
Bioorg Med Chem Lett 15: 5446-9 (2005)
Astrazeneca
Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
Bioorg Med Chem Lett 15: 5124-8 (2005)
Merck Research Laboratories
Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.
Bioorg Med Chem Lett 15: 5293-7 (2005)
Abbott Laboratories
Preparation of human Melanocortin-4 receptor agonist libraries: linear peptides X-Y-DPhe7-Arg8-Trp(or 2-Nal)9-Z-NH2.
Bioorg Med Chem Lett 15: 5504-8 (2005)
Roche Research Center
Surfing the piperazine core of tricyclic farnesyltransferase inhibitors.
Bioorg Med Chem Lett 15: 5537-43 (2005)
Pharmacopeia
Structure-based discovery of a new class of Hsp90 inhibitors.
Bioorg Med Chem Lett 15: 5187-91 (2005)
Vernalis (R&D)
Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1).
Bioorg Med Chem Lett 15: 5526-30 (2005)
Eli Lilly
Synthesis and monoamine transporter affinity of 3-aryl substituted trop-2-enes.
Bioorg Med Chem Lett 15: 5488-93 (2005)
University of Illinois At Chicago
Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors.
Bioorg Med Chem Lett 15: 5514-6 (2005)
Gyeongsang National University
Biaryl diamides as potent melanin concentrating hormone receptor 1 antagonists.
Bioorg Med Chem Lett 15: 5234-6 (2005)
Schering-Plough Research Institute
Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions.
Bioorg Med Chem Lett 15: 5120-3 (2005)
National Research Council of Canada
Novel 7-methoxy-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors.
Bioorg Med Chem Lett 15: 5335-9 (2005)
Ucb Pharma
Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.
Biochemistry 44: 13415-24 (2005)
Probiodrug
Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
Bioorg Med Chem Lett 15: 5467-73 (2005)
Genomics Institute of The Novartis Research Foundation
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.
Bioorg Med Chem Lett 15: 5247-52 (2005)
Jacobus Pharmaceutical
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
Bioorg Med Chem Lett 15: 5160-4 (2005)
Novartis Institutes For Biomedical Research
Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases.
Bioorg Med Chem Lett 15: 5474-7 (2005)
Imclone Systems
Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
Bioorg Med Chem Lett 15: 5202-6 (2005)
Johnson & Johnson Pharmaceutical Research and Development
Synthesis and pharmacological evaluation of 1H-imidazoles as ligands for the estrogen receptor and cytotoxic inhibitors of the cyclooxygenase.
J Med Chem 48: 6516-21 (2005)
Free University of Berlin
Design, synthesis, and preliminary pharmacological evaluation of a set of small molecules that directly activate gi proteins.
J Med Chem 48: 6491-503 (2005)
University of Florence
Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
J Med Chem 48: 6482-90 (2005)
Abbott Laboratories
Synthesis and structure-activity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovirus encoded chemokine receptor US28.
J Med Chem 48: 6461-71 (2005)
Vrije Universiteit
Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci.
J Med Chem 48: 6442-53 (2005)
Bristol-Myers Squibb Medical Imaging
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.
J Med Chem 48: 6430-41 (2005)
Metabasis Therapeutics
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor.
J Med Chem 48: 6423-9 (2005)
Northeastern University
Synthesis and antiinflammatory activity of coumarin derivatives.
J Med Chem 48: 6400-8 (2005)
Aristotle University of Thessaloniki
Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
J Med Chem 48: 6386-92 (2005)
Northeastern University
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
J Med Chem 48: 6379-85 (2005)
University of Oporto
Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
J Med Chem 48: 6350-65 (2005)
Wayne State University
Design, synthesis, and activity of analogues of phosphinothricin as inhibitors of glutamine synthetase.
J Med Chem 48: 6340-9 (2005)
Wroclaw University of Technology
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
J Med Chem 48: 6326-39 (2005)
Pfizer
Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids.
J Med Chem 48: 6315-25 (2005)
Università
Simple but highly effective three-dimensional chemical-feature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA polymerase inhibitors.
J Med Chem 48: 6304-14 (2005)
Sapienza University of Rome
5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
J Med Chem 48: 6261-70 (2005)
Bristol-Myers Squibb
Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
J Med Chem 48: 6229-35 (2005)
Schering-Plough Research Institute
Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies.
J Med Chem 48: 6220-8 (2005)
Université
Ligand recognition by RAR and RXR receptors: binding and selectivity.
J Med Chem 48: 6212-9 (2005)
Universidad De Santiago De Compostela
Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases.
J Med Chem 48: 6194-201 (2005)
Cnrs Umr-8113
Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
J Med Chem 48: 6178-93 (2005)
Sanofi-Aventis Deutschland
Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2.
J Med Chem 48: 6174-7 (2005)
Oxagen
Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3.
J Med Chem 48: 6169-73 (2005)
Merck Research Laboratories
Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy.
Bioorg Med Chem Lett 15: 5176-81 (2005)
Santhera Pharmaceuticals
Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Bioorg Med Chem Lett 15: 5266-9 (2005)
Merck
Rapamycin analogs with reduced systemic exposure.
Bioorg Med Chem Lett 15: 5340-3 (2005)
Abbott Laboratories
Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors.
Bioorg Med Chem Lett 15: 5298-302 (2005)
Virginia Commonwealth University
Inhibitors of the serotonin transporter protein (SERT): the design and synthesis of biotinylated derivatives of 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indoles. High-affinity serotonergic ligands for conjugation with quantum dots.
Bioorg Med Chem Lett 15: 5307-10 (2005)
Vanderbilt University
A new antitumor compound from the plant Oryctanthus sp. as a VEGF receptor binding inhibitor.
Bioorg Med Chem Lett 15: 4907-9 (2005)
Schering-Plough Research Institute
Structure-activity relationship studies on a series of cyclohexylpiperazines bearing a phanylacetamide as ligands of the human melanocortin-4 receptor.
Bioorg Med Chem Lett 15: 5237-40 (2005)
Neurocrine Biosciences
Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Bioorg Med Chem Lett 15: 4979-84 (2005)
Gnf
Synthesis of desthio prenylcysteine analogs: sulfur is important for biological activity.
Bioorg Med Chem Lett 15: 5080-3 (2005)
Purdue University
Synthesis and HIV-1 integrase inhibitory activities of caffeic acid dimers derived from Salvia officinalis.
Bioorg Med Chem Lett 15: 5053-6 (2005)
Université
3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
Bioorg Med Chem Lett 15: 5061-4 (2005)
Merck Research Laboratories
Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
Bioorg Med Chem Lett 15: 5170-5 (2005)
University of Ljubljana
New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif.
Bioorg Med Chem Lett 15: 5517-20 (2005)
Kobe Gakuin University
Structure-based discovery of a boronic acid bioisostere of combretastatin A-4.
Chem Biol 12: 1007-14 (2005)
University of Virginia
Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.
Chem Biol 12: 973-80 (2005)
University of Dundee
Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents.
J Nat Prod 68: 1437-40 (2005)
Merck Research Laboratories
Design, synthesis, and evaluation of octahydropyranopyrrole-based inhibitors of mammalian ribonucleotide reductase.
Bioorg Med Chem Lett 15: 5146-9 (2005)
University of Pennsylvania
An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2.
Chembiochem 6: 1882-90 (2005)
Progen Industries
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
Bioorg Med Chem Lett 15: 4889-97 (2005)
Pfizer
Solid-phase binding assays of peptides using EGFP-Src SH2 domain fusion protein and biotinylated Src SH2 domain.
Bioorg Med Chem Lett 15: 4994-7 (2005)
University of Rhode Island
Inhibitors of phenylethanolamine N-methyltransferase devoid of alpha2-adrenoceptor affinity.
Bioorg Med Chem Lett 15: 5319-23 (2005)
University of Kansas
Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
Bioorg Med Chem Lett 15: 5274-9 (2005)
Locus Pharmaceuticals
Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases.
Bioorg Med Chem Lett 15: 4944-8 (2005)
China Pharmaceutical University
Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides.
Bioorg Med Chem Lett 15: 4910-4 (2005)
Roche Research Center
A lead compound for the development of ABA 8'-hydroxylase inhibitors.
Bioorg Med Chem Lett 15: 5226-9 (2005)
Gifu University
Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives.
Bioorg Med Chem Lett 15: 4973-8 (2005)
Eli Lilly
Design, synthesis, and enzymatic property of a sulfur-substituted analogue of trigalacturonic acid.
Bioorg Med Chem Lett 15: 4932-5 (2005)
Hirosaki University
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
Bioorg Med Chem Lett 15: 4862-6 (2005)
Università
A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.
Bioorg Med Chem Lett 15: 4989-93 (2005)
Glaxosmithkline
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Bioorg Med Chem Lett 15: 5241-6 (2005)
Merck Frosst Centre For Therapeutic Research
N-[(3S)-1-benzylpyrrolidin-3-yl]-(2-thienyl)benzamides: human dopamine D4 ligands with high affinity for the 5-HT2A receptor.
Bioorg Med Chem Lett 15: 5253-6 (2005)
Nps Pharmaceuticals
Phosphinate, sulfonate, and sulfonamidate dipeptides as potential inhibitors of Escherichia coli aminopeptidase N.
Bioorg Med Chem Lett 15: 5150-3 (2005)
Miami University
Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine.
Bioorg Med Chem Lett 15: 4967-72 (2005)
M.D. University
2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV.
Bioorg Med Chem Lett 15: 5257-61 (2005)
Glaxosmithkline
High affinity ligands for the alpha7 nicotinic receptor that show no cross-reactivity with the 5-HT3 receptor.
Bioorg Med Chem Lett 15: 4727-30 (2005)
Eli Lilly
Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2.
Bioorg Med Chem Lett 15: 4985-8 (2005)
Wyeth Research
Structure-based design of 7-carbamate analogs of geldanamycin.
Bioorg Med Chem Lett 15: 5016-21 (2005)
Kosan Biosciences
Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.
Bioorg Med Chem Lett 15: 4656-61 (2005)
Sapienza University of Rome
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
Bioorg Med Chem Lett 15: 4872-6 (2005)
Università
The synthesis and biological evaluation of dopamine transporter inhibiting activity of substituted diphenylmethoxypiperidines.
Bioorg Med Chem Lett 15: 4915-8 (2005)
Wake Forest University Health Sciences
Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships.
Bioorg Med Chem Lett 15: 5288-92 (2005)
Wyeth Research
Thyrotropin-releasing hormone (TRH) analogues that exhibit selectivity to TRH receptor subtype 2.
J Med Chem 48: 6162-5 (2005)
National Institute of Pharmaceutical Education and Research
Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.
J Med Chem 48: 6140-55 (2005)
Purdue University
Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
J Med Chem 48: 6128-39 (2005)
University of Illinois At Urbana-Champaign
Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations.
J Med Chem 48: 6090-106 (2005)
Uppsala University
Molecular modeling, synthesis, and preliminary biological evaluation of glutathione-S-transferase inhibitors as potential therapeutic agents.
J Med Chem 48: 6084-9 (2005)
Università
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
J Med Chem 48: 6066-83 (2005)
Abbott Laboratories
Rational design, synthesis, and characterization of novel inhibitors for human beta1,4-galactosyltransferase.
J Med Chem 48: 6054-65 (2005)
Hokkaido University
Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
J Med Chem 48: 6023-34 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
A new pyridazine series of GABAA alpha5 ligands.
J Med Chem 48: 6004-11 (2005)
Merck Sharp & Dohme Research Laboratories
Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
J Med Chem 48: 5989-6003 (2005)
University of California
F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain.
J Med Chem 48: 5980-8 (2005)
University of Pennsylvania
Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
J Med Chem 48: 5966-79 (2005)
Takeda Pharmaceutical
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
J Med Chem 48: 5942-54 (2005)
Cardiff University
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist
J Med Chem 48: 5921-31 (2005)
Boehringer Ingelheim Pharma
4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors.
J Med Chem 48: 5909-20 (2005)
Wyeth Research
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
J Med Chem 48: 5900-8 (2005)
Bayer Healthcare
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.
J Med Chem 48: 5888-91 (2005)
Abbott Laboratories
Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.
J Med Chem 48: 5884-7 (2005)
Schering-Plough Research Institute
Complexation of ferrocene derivatives by the cucurbit[7]uril host: a comparative study of the cucurbituril and cyclodextrin host families.
J Am Chem Soc 127: 12984-9 (2005)
University of Miami
Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
Bioorg Med Chem Lett 15: 4741-4 (2005)
Merck Frosst Centre For Therapeutic Research
Bis(indole) alkaloids as sortase A inhibitors from the sponge Spongosorites sp.
Bioorg Med Chem Lett 15: 4927-31 (2005)
Seoul National University
Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides.
Bioorg Med Chem Lett 15: 5012-5 (2005)
Astrazeneca
Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.
Bioorg Med Chem Lett 15: 5035-8 (2005)
Merck Research Laboratories
Activity and QSAR study of baogongteng A and its derivatives as muscarinic agonists.
Bioorg Med Chem Lett 15: 4814-8 (2005)
Shanghai Second Medical University
Identification of a potent and selective 5-HT1B receptor antagonist.
Bioorg Med Chem Lett 15: 4708-12 (2005)
Glaxosmithkline
(4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.
Bioorg Med Chem Lett 15: 5003-6 (2005)
Wyeth Research
Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography.
Bioorg Med Chem Lett 15: 4699-702 (2005)
University of California Los Angeles
An efficient synthesis of argifin: a natural product chitinase inhibitor with chemotherapeutic potential.
Bioorg Med Chem Lett 15: 4717-21 (2005)
University of Dundee
Preparation of 3-spirocyclic indolin-2-ones as ligands for the ORL-1 receptor.
Bioorg Med Chem Lett 15: 5022-6 (2005)
Johnson & Johnson Pharmaceutical Research and Development
Pyrazolopyridinones as functionally selective GABAA ligands.
Bioorg Med Chem Lett 15: 4998-5002 (2005)
Merck Sharp & Dohme Research Laboratories
Synthesis and SAR of highly selective MMP-13 inhibitors.
Bioorg Med Chem Lett 15: 4961-6 (2005)
Wyeth Research
Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
Bioorg Med Chem Lett 15: 4809-13 (2005)
Biogen Idec
The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold.
Bioorg Med Chem Lett 15: 4666-70 (2005)
University College London
Bioisosteric phentolamine analogs as potent alpha-adrenergic antagonists.
Bioorg Med Chem Lett 15: 4691-5 (2005)
Chungbuk National University
SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors.
Bioorg Med Chem Lett 15: 4854-7 (2005)
4Sc
Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases.
Bioorg Med Chem Lett 15: 4842-5 (2005)
University of Alberta
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions.
Bioorg Med Chem Lett 15: 4745-51 (2005)
Maxim Pharmaceuticals
Synthesis of potent and selective serotonin 5-HT1B receptor ligands.
Bioorg Med Chem Lett 15: 4786-9 (2005)
Columbia University College of Physicians and Surgeons
Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors.
Bioorg Med Chem Lett 15: 4713-6 (2005)
Pfizer
Novel indole alpha-methylene-gamma-lactones as potent inhibitors for AKT-mTOR signaling pathway kinases.
Bioorg Med Chem Lett 15: 4799-802 (2005)
Chinese Academy of Sciences
Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase.
Bioorg Med Chem Lett 15: 4685-90 (2005)
Universidad De Buenos Aires
Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Bioorg Med Chem Lett 15: 4696-8 (2005)
Imclone Systems
Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.
Bioorg Med Chem Lett 15: 4867-71 (2005)
Glaxosmithkline
Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors.
Bioorg Med Chem Lett 15: 4790-3 (2005)
Johnson & Johnson Pharmaceutical Research and Development
Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-beta.
Bioorg Med Chem Lett 15: 4703-7 (2005)
Cell Therapeutics
The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases.
Bioorg Med Chem Lett 16: 2337-40 (2006)
Pfizer
Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Bioorg Med Chem Lett 15: 5095-9 (2005)
Astrazeneca R&D SöDertäLje
Synthesis and pharmacological evaluation of Tic-hydantoin derivatives as selective sigma1 ligands. Part 1.
Bioorg Med Chem Lett 15: 4833-7 (2005)
Université
Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
Bioorg Med Chem Lett 15: 4794-8 (2005)
Solvay Pharma
Synthesis and pharmacological evaluation of Tic-hydantoin derivatives as selective sigma1 ligands. Part 2.
Bioorg Med Chem Lett 15: 4828-32 (2005)
Université
Synthesis and evaluation of 18F-labeled dopamine D3 receptor ligands as potential PET imaging agents.
Bioorg Med Chem Lett 15: 4819-23 (2005)
University of Erlangen-Nuremberg
Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.
Bioorg Med Chem Lett 15: 4411-6 (2005)
Merck Research Laboratories
Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.
Bioorg Med Chem Lett 15: 4421-6 (2005)
Cnrs Umr 6052
Design and synthesis of phthalimide-type histone deacetylase inhibitors.
Bioorg Med Chem Lett 15: 4427-31 (2005)
The University of Tokyo Yayoi
1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors.
Bioorg Med Chem Lett 15: 4432-7 (2005)
Eli Lilly
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
Bioorg Med Chem Lett 15: 4438-46 (2005)
Kadir Has University
4-Phenylcoumarins as HIV transcription inhibitors.
Bioorg Med Chem Lett 15: 4447-50 (2005)
Instituto De Salud Carlos Iii
A chemical strategy to promote helical peptide-protein interactions involved in apoptosis.
Bioorg Med Chem Lett 15: 4467-9 (2005)
University of Illinois At Urbana-Champaign
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
J Pharmacol Exp Ther 315: 1278-87 (2005)
Acadia Pharmaceuticals
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2).
J Med Chem 48: 5853-68 (2005)
Pfizer
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1).
J Med Chem 48: 5837-52 (2005)
Pharmacia
Novel potent antagonists of transient receptor potential channel, vanilloid subfamily member 1: structure-activity relationship of 1,3-diarylalkyl thioureas possessing new vanilloid equivalents.
J Med Chem 48: 5823-36 (2005)
Seoul National University
Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography.
J Med Chem 48: 5813-22 (2005)
National Institute On Drug Abuse
Modifications to the tetracaine scaffold produce cyclic nucleotide-gated channel blockers with widely varying efficacies.
J Med Chem 48: 5805-12 (2005)
Oregon Health and Science University
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
J Med Chem 48: 5794-804 (2005)
Pharmacia
Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
J Med Chem 48: 5780-93 (2005)
Neurocrine Biosciences
Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
J Med Chem 48: 5771-9 (2005)
Friedrich-Alexander University
E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
J Med Chem 48: 5749-70 (2005)
University of Bath
Conformationally constrained analogues of diacylglycerol (DAG). 25. Exploration of the sn-1 and sn-2 carbonyl functionality reveals the essential role of the sn-1 carbonyl at the lipid interface in the binding of DAG-lactones to protein kinase C.
J Med Chem 48: 5738-48 (2005)
National Cancer Institute-Frederick
Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.
J Med Chem 48: 5728-37 (2005)
Pfizer
Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II.
J Med Chem 48: 5721-7 (2005)
Istituto Di Biostrutture E Bioimmagini-Cnr
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
J Med Chem 48: 5705-20 (2005)
Chiesi Farmaceutici
6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.
J Med Chem 48: 5684-97 (2005)
7Tm Pharma
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
J Med Chem 48: 5666-74 (2005)
University of Basel
Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
J Med Chem 48: 5659-65 (2005)
Institute of Genetics and Molecular and Cellular Biology (Igbmc)
4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.
J Med Chem 48: 5644-7 (2005)
Gsk
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
J Med Chem 48: 5639-43 (2005)
Bristol-Myers Squibb
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
J Med Chem 48: 5613-38 (2005)
The Scripps Research Institute
Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.
Bioorg Med Chem Lett 15: 4780-5 (2005)
Wyeth Research
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.
Bioorg Med Chem 13: 6571-7 (2005)
Ohio State University
The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.
Bioorg Med Chem Lett 15: 4752-6 (2005)
Pfizer
Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis.
Bioorg Med Chem Lett 15: 4574-8 (2005)
Merck Research Laboratories
Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles.
Bioorg Med Chem Lett 15: 4681-4 (2005)
Wyeth Research
Phaeochromycins A-E, anti-inflammatory polyketides isolated from the soil actinomycete Streptomyces phaeochromogenes LL-P018.
J Nat Prod 68: 1262-5 (2005)
Wyeth Research
Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources.
J Nat Prod 68: 1247-52 (2005)
Merck Research Laboratories
Sesterterpenoids, terretonins A-D, and an alkaloid, asterrelenin, from Aspergillus terreus.
J Nat Prod 68: 1243-6 (2005)
The Chinese Academy of Sciences
Iminosugar-producing Thai medicinal plants.
J Nat Prod 68: 1238-42 (2005)
Hokuriku University
A fragment-based approach to understanding inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
Chembiochem 6: 1866-74 (2005)
University of Bristol
Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies.
Bioorg Med Chem Lett 15: 4417-20 (2005)
Schering-Plough Research Institute
New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.
Bioorg Med Chem Lett 15: 4770-3 (2005)
Pfizer
Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
Bioorg Med Chem Lett 15: 4589-93 (2005)
Merck Research Laboratories
Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.
Bioorg Med Chem Lett 15: 4463-6 (2005)
University of Kentucky
Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.
Bioorg Med Chem Lett 15: 4515-9 (2005)
Schering-Plough Research Institute
Privileged structure-based ligands for melanocortin receptors-tetrahydroquinolines, indoles, and aminotetralines.
Bioorg Med Chem Lett 15: 4459-62 (2005)
Eli Lilly
Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
Bioorg Med Chem Lett 15: 4475-8 (2005)
Schering-Plough Research Institute
Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.
Bioorg Med Chem 13: 6693-702 (2005)
Johnson & Johnson Pharmaceutical
Trifluoromethyl group as a pharmacophore: effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand.
Bioorg Med Chem Lett 15: 4761-9 (2005)
Boehringer Ingelheim Pharmaceuticals
New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Bioorg Med Chem Lett 15: 4774-9 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
J Med Chem 48: 5608-11 (2005)
University of Cagliari
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
J Med Chem 48: 5589-99 (2005)
Merck Research Laboratories
Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
J Med Chem 48: 5580-8 (2005)
Boehringer Ingelheim (Canada)
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
J Med Chem 48: 5551-60 (2005)
University of Kentucky
Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety.
J Med Chem 48: 5543-50 (2005)
St. Jude Children'S Research Hospital
Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
J Med Chem 48: 5536-42 (2005)
Monash University (Parkville Campus)
Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
J Med Chem 48: 5530-5 (2005)
The Ohio State University
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
J Med Chem 48: 5509-19 (2005)
Università
New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.
J Med Chem 48: 5495-503 (2005)
Università
Development of a three-dimensional model for the N-methyl-D-aspartate NR2A subunit.
J Med Chem 48: 5489-94 (2005)
University of Milan
A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.
J Med Chem 48: 5437-47 (2005)
North Dakota State University
Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure.
J Med Chem 48: 5419-22 (2005)
Glaxosmithkline
Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.
J Med Chem 48: 5412-4 (2005)
Leo Pharma
A molecular target for suppression of the evolution of antibiotic resistance: inhibition of the Escherichia coli RecA protein by N(6)-(1-naphthyl)-ADP.
J Med Chem 48: 5408-11 (2005)
University of North Carolina at Chapel Hill
Farnesoid X receptor: from structure to potential clinical applications.
J Med Chem 48: 5383-403 (2005)
University of Perugia
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
NA
Lilly Research Labs
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
Bioorg Med Chem Lett 15: 4564-9 (2005)
Merck Research Laboratories
A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.
Bioorg Med Chem Lett 15: 4550-4 (2005)
Merck Research Laboratories
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
Bioorg Med Chem Lett 15: 4579-84 (2005)
Pharmaceutical Research Institute
Heteroaromatic side-chain analogs of pregabalin.
Bioorg Med Chem Lett 16: 2329-32 (2006)
Pgrd Michigan Laboratories
1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors.
Bioorg Med Chem Lett 15: 4604-10 (2005)
Dipartimento Di Scienze Farmaceutiche
4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors.
Bioorg Med Chem Lett 15: 4221-5 (2005)
Fujisawa Pharmaceutical
ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Bioorg Med Chem Lett 15: 4520-5 (2005)
Wyeth Research
Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles.
Bioorg Med Chem Lett 15: 4299-303 (2005)
Dainippon Pharmaceutical
Hydroxylated N-alkyl-4-piperidinyl-2,3-diarylpyrrole derivatives as potent broad-spectrum anticoccidial agents.
Bioorg Med Chem Lett 15: 4570-3 (2005)
Merck Research Laboratories
8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity.
Bioorg Med Chem Lett 15: 4560-3 (2005)
Pfizer
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
Bioorg Med Chem Lett 15: 4180-4 (2005)
Schering-Plough Research Institute
Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7.
Bioorg Med Chem Lett 15: 4239-42 (2005)
Activx Biosciences
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.
Bioorg Med Chem Lett 15: 4201-5 (2005)
Bayer Healthcare
Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists.
Bioorg Med Chem Lett 15: 4174-9 (2005)
Abbott Laboratories
Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors.
Bioorg Med Chem Lett 15: 4256-60 (2005)
Activx Biosciences
Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
Bioorg Med Chem Lett 15: 4345-9 (2005)
Wyeth Research
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
J Med Chem 48: 5373-7 (2005)
Novartis Institutes For Biomedical Research
Design and synthesis of 4-(alpha-hydroxymalonyl)phenylalanine as a new phosphotyrosyl mimetic and its use in growth factor receptor bound 2 src-homology 2 (Grb2 SH2) domain-binding peptides.
J Med Chem 48: 5369-72 (2005)
National Cancer Institute-Frederick
High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
J Med Chem 48: 5337-48 (2005)
Hadassah Hebrew University
Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
J Med Chem 48: 5329-36 (2005)
Duquesne University
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
J Med Chem 48: 5321-8 (2005)
Institute of Cancer Research
Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.
J Med Chem 48: 5305-20 (2005)
Eli Lilly
Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.
J Med Chem 48: 5295-304 (2005)
Abbott Laboratories
Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.
J Med Chem 48: 5279-94 (2005)
Toray Industries
Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
J Med Chem 48: 5257-68 (2005)
Chuq-Pavillon Chul and Universit£
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
J Med Chem 48: 5243-56 (2005)
University of Bath
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
J Med Chem 48: 5232-42 (2005)
Wockhardt
2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino)- phenylcarbamoylsulfanyl]propionic acid and its derivatives as a novel class of glutathione reductase inhibitors.
J Med Chem 48: 5224-31 (2005)
South Dakota State University
Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents.
J Med Chem 48: 5215-23 (2005)
Maxim Pharmaceuticals
Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics.
J Med Chem 48: 5175-90 (2005)
Universite De Montreal At Succursale Centre-Ville
Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.
J Med Chem 48: 5162-74 (2005)
University of Pisa
6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency.
J Med Chem 48: 5131-9 (2005)
University of Virginia
Ligand selectivity for the acetylcholine binding site of the rat alpha4beta2 and alpha3beta4 nicotinic subtypes investigated by molecular docking.
J Med Chem 48: 5123-30 (2005)
Swiss Federal Institute of Technology Zurich
Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations.
J Med Chem 48: 5108-11 (2005)
University of ZüRich
Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
J Med Chem 48: 5104-7 (2005)
Neurocrine Biosciences
Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone.
J Med Chem 48: 5100-3 (2005)
Inotek Pharmaceuticals
A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-ethyl-2-[11C]methyl-6-quinolinyl)(cis- 4-methoxycyclohexyl)methanone.
J Med Chem 48: 5096-9 (2005)
Columbia University College of Physicians and Surgeons
Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget.
J Med Chem 48: 5092-5 (2005)
Women'S Health Research Institute
Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
J Med Chem 48: 5088-91 (2005)
Schering-Plough Research Institute
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
J Med Chem 48: 5059-87 (2005)
University of Louvain
Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
J Pharmacol Exp Ther 315: 821-7 (2005)
University of Rochester
Analogs of a potent maxi-K potassium channel opener with an improved inhibitory profile toward cytochrome P450 isozymes.
Bioorg Med Chem Lett 15: 4286-90 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Bioorg Med Chem Lett 15: 4555-9 (2005)
Organix
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett 15: 4226-9 (2005)
Astrazeneca
2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.
Bioorg Med Chem Lett 15: 4230-4 (2005)
Carlsson Research
Cyclic sulfamide gamma-secretase inhibitors.
Bioorg Med Chem Lett 15: 4212-6 (2005)
Merck Sharp and Dohme Research Laboratories
Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: squaryldiamide as a new potential bioisostere of unsubstituted guanidine.
Bioorg Med Chem Lett 15: 4243-6 (2005)
University of Massachusetts Medical School
Synthesis and antipicornavirus activity of (R)- and (S)-1-[5-(4'-chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one.
Bioorg Med Chem Lett 15: 4206-11 (2005)
National Health Research Institutes
Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells.
J Pharmacol Exp Ther 315: 839-48 (2005)
Institute of Cell Signaling
Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues.
Bioorg Med Chem Lett 15: 4169-73 (2005)
Harvard Medical School
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Proc Natl Acad Sci U S A 102: 11011-6 (2005)
Ambit
Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1beta-converting enzyme.
Bioorg Med Chem Lett 15: 4322-6 (2005)
Procter & Gamble Pharmaceuticals
Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1beta synthesis.
Bioorg Med Chem Lett 15: 4291-4 (2005)
Procter & Gamble Pharmaceuticals
Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors.
Bioorg Med Chem Lett 15: 4336-41 (2005)
Affymax
Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors.
Bioorg Med Chem Lett 15: 3992-5 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
J Pharmacol Exp Ther 315: 711-21 (2005)
F. Hoffmann-La Roche
Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists.
Bioorg Med Chem Lett 15: 4350-3 (2005)
Merck Research Laboratories
3-(2-Aminoethyl)pyridine analogs as alpha4beta2 nicotinic cholinergic receptor ligands.
Bioorg Med Chem Lett 15: 4308-12 (2005)
Virginia Commonwealth University
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
Bioorg Med Chem Lett 15: 3821-7 (2005)
Universita Degli Studi
8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Bioorg Med Chem Lett 15: 4370-4 (2005)
Glaxosmithkline
Epibatidine analogues as selective ligands for the alpha(x)beta2-containing subtypes of nicotinic acetylcholine receptors.
Bioorg Med Chem Lett 15: 4385-8 (2005)
Columbia University College of Physicians and Surgeons
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
Bioorg Med Chem Lett 15: 3828-33 (2005)
Kochi Medical School
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation.
Chem Biol 12: 811-23 (2005)
Harvard Medical School
Synthesis of tripeptides as potent Yersinia protein tyrosine phosphatase inhibitors.
Bioorg Med Chem Lett 15: 4037-42 (2005)
Nih
Influence of acid surrogates toward potency of VLA-4 antagonist.
Bioorg Med Chem Lett 15: 4053-6 (2005)
Merck Research Laboratories
Inhibition of mandelate racemase by the substrate-intermediate-product analogue 1,1-diphenyl-1-hydroxymethylphosphonate.
Bioorg Med Chem Lett 15: 4342-4 (2005)
Dalhousie University
Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption.
Bioorg Med Chem Lett 15: 3957-61 (2005)
Pfizer
Structural revision of aspernigrin A, reisolated from Cladosporium herbarum IFB-E002.
J Nat Prod 68: 1106-8 (2005)
Nanjing University
Latifolians A and B, novel JNK3 kinase inhibitors from the Papua New Guinean plant Gnetum latifolium.
J Nat Prod 68: 1080-2 (2005)
Griffith University
Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674.
J Nat Prod 68: 1061-5 (2005)
Mitsubishi Pharma
Expanding the ChemGPS chemical space with natural products.
J Nat Prod 68: 985-91 (2005)
Uppsala University
Acylphloroglucinol derivatives from Mahurea palustris.
J Nat Prod 68: 979-84 (2005)
National Center For Scientific Research (Cnrs)-Pierre Fabre
Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
J Med Chem 48: 5052-5 (2005)
University of Innsbruck
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
J Med Chem 48: 5025-37 (2005)
Bristol-Myers Squibb Pharmaceutical Research Institute
New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
J Med Chem 48: 5001-8 (2005)
Università
Synthesis and radioligand binding studies of C-5- and C-8-substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums as SK channel blockers related to N-methyl-laudanosine and N-methyl-noscapine.
J Med Chem 48: 4972-82 (2005)
University of Li£Ge
Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner.
J Med Chem 48: 4962-71 (2005)
Wayne State University
Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity.
J Med Chem 48: 4931-46 (2005)
Università
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
J Med Chem 48: 4919-30 (2005)
University of Tennessee Health Science Center
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists.
J Med Chem 48: 4910-8 (2005)
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
J Med Chem 48: 4892-909 (2005)
Johnson & Johnson Pharmaceutical
Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase.
J Med Chem 48: 4871-81 (2005)
Universidad De Santiago De Compostela
Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
J Med Chem 48: 4851-60 (2005)
Salk Institute
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.
J Med Chem 48: 4842-50 (2005)
Instituto De QuíMica MéDica (Csic)
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
J Med Chem 48: 4834-41 (2005)
Università
Control of protein-protein interactions: structure-based discovery of low molecular weight inhibitors of the interactions between Pin1 WW domain and phosphopeptides.
J Med Chem 48: 4815-23 (2005)
Cnrs-University of Lille 2 Umr 8525
Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis.
J Med Chem 48: 4793-802 (2005)
Universit£T Heidelberg
Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases.
J Med Chem 48: 4783-92 (2005)
Sanofi-Aventis
Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
J Med Chem 48: 4772-82 (2005)
University of Kuopio
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
J Med Chem 48: 4765-71 (2005)
The University of Iowa
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
J Med Chem 48: 4754-64 (2005)
University of Innsbruck
Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.
J Med Chem 48: 4750-3 (2005)
Fujisawa Pharmaceutical
Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity.
J Med Chem 48: 4746-9 (2005)
Schering-Plough Research Institute
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
J Med Chem 48: 4705-45 (2005)
The Danish University of Pharmaceutical Sciences
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
J Am Chem Soc 127: 10191-6 (2005)
Yale University
Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors.
Bioorg Med Chem Lett 15: 3886-90 (2005)
Merck Frosst Canada
Ligands with dual vitamin D3-agonistic and androgen-antagonistic activities.
Bioorg Med Chem Lett 15: 4327-31 (2005)
The University of Tokyo
Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2.
Mol Pharmacol 68: 974-82 (2005)
Wyeth Research
Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles.
Bioorg Med Chem Lett 15: 4048-52 (2005)
Universitá
Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
Bioorg Med Chem Lett 15: 4085-90 (2005)
Sumitomo Pharmaceuticals
Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif.
Bioorg Med Chem Lett 15: 4023-8 (2005)
Merck Research Laboratories
1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists.
Bioorg Med Chem Lett 15: 3701-6 (2005)
Neurocrine Biosciences
Identification of potent type I MetAPs inhibitors by simple bioisosteric replacement. Part 2: SAR studies of 5-heteroalkyl substituted TCAT derivatives.
Bioorg Med Chem Lett 15: 4130-5 (2005)
Shanghai Graduate School of The Chinese Academy of Sciences
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
Bioorg Med Chem Lett 15: 4110-3 (2005)
Clemson University
Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
Bioorg Med Chem Lett 15: 4068-72 (2005)
Merck Research Laboratories
Identification of potent and selective MMP-13 inhibitors.
Bioorg Med Chem Lett 15: 4105-9 (2005)
Wyeth Research
The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion.
Bioorg Med Chem Lett 15: 3874-80 (2005)
University of Florida
Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists.
Bioorg Med Chem Lett 15: 4136-42 (2005)
Seoul National University
Inhibition of tumor cell proliferation by thieno[2,3-d]pyrimidin-4(1H)-one-based analogs.
Bioorg Med Chem Lett 15: 3763-6 (2005)
Wyeth Research
High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
J Comb Chem 7: 611-7 (2005)
Uppsala University
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
Bioorg Med Chem Lett 15: 3787-90 (2005)
Pfizer
Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.
Bioorg Med Chem Lett 15: 3853-6 (2005)
Taisho Pharmaceutical
Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.
Bioorg Med Chem Lett 15: 4014-8 (2005)
Glaxosmithkline
Phenylpyrroles, a new chemolibrary virtual screening class of 5-HT7 receptor ligands.
Bioorg Med Chem Lett 15: 3753-7 (2005)
Université
New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity.
Bioorg Med Chem Lett 15: 4019-22 (2005)
Unité
New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
J Med Chem 48: 4697-701 (2005)
Università
Second generation transition state analogue inhibitors of human 5'-methylthioadenosine phosphorylase.
J Med Chem 48: 4679-89 (2005)
Industrial Research
The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination.
J Med Chem 48: 4663-9 (2005)
University of Piemonte Orientale
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
J Med Chem 48: 4628-53 (2005)
University of Auckland
Curated by BindingDB
Curated by ChEMBL